PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

COMMUNICATION OF
INTERNATIONAL APPLICATIONS

(PCT Article 20)

To:

United States Patent and Trademark
Office
(Box PCT)
Washington D.C. 20231
United States of America

in its capacity as designated Office

Date of mailing:
04 May 1995 (04.05.95)

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:
PCT/US94/09024

International publication no.:
WO95/06728

CORRECTED VERSION
VERSION CORRIGEE

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

Authorized officer:
J. Zahra
Telephone No.: (41-22) 730.91.11

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING DOCUMENT TRANSMITTED

To:

United States Patent and Trademark Office
(Box PCT)
Washington D.C. 20231
United States of America

in its capacity as elected Office

Date of mailing (day/month/year)	
24 October 1995 (24.10.95)	
International application No. PCT/US94/09024	**International filing date** (day/month/year) 05 August 1994 (05.08.94)
Applicant IMMULOGIC PHARMACEUTICAL CORPORATION et al	

The International Bureau transmits herewith the following documents and number thereof:

_____ copy of the international preliminary examination report and annexes (Article 36(3)(a))

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

P. Asseeff

Telephone No.: (41-22) 730.91.11

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Washington D.C. 20231
United States of America

in its capacity as elected Office

Date of mailing: 06 April 1995 (06.04.95)	
International application No.: PCT/US94/09024	Applicant's or agent's file reference: 075.1PCT
International filing date: 05 August 1994 (05.08.94)	Priority date: 13 August 1993 (13.08.93)
Applicant: GRIFFITH, Irwin, J. et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

09 March 1995 (09.03.95)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer: T. Zhao Telephone No.: (41-22) 730.91.11

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
IMI-040CP2PC		

International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/US 94/ 09024	05/08/1994	13/08/1993

International Patent Classification (IPC) or national classification and IPC

C12N15/29

Applicant

IMMULOGIC PHARMACEUTICAL CORPORATION et al.

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

[X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consists of a total of 1 sheets.

3. This report contains indications and corresponding pages relating to the following items:

- I [X] Basis of the report
- II [ ] Priority
- III [X] Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV [ ] Lack of unity of invention
- V [X] Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI [X] Certain documents cited
- VII [ ] Certain defects in the international application
- VIII [X] Certain observations on the international application

Date of submission of the demand	Date of completion of this report
09/03/1995	11.10.95

Name and mailing address of the IPEA

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk - Netherlands
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

M. Cupido

Telephone No. (+31-70) 340-3374

I. Basis of the report

1. This report has been drawn up on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed" and are not annexed to the report since they do not contain amendments.):

[X] the description,
pages 1-75 ,as originally filed.

[X] the claims,
Nos. 6-48 ,as originally filed.
Nos. 1-5 ,filed with the letter of 18 August 1995

[X] the drawings,
sheets 1/20-20/20 ,as originally filed.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The question whether the claimed invention appears to be novel, to involve an inventive step, or to be industrially applicable have not been and will not be examined in respect of:

[X] claims 44-48

because no international search report has been established for claims 44-48.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-43	YES
	Claims	NO
Inventive Step (IS)	Claims 1-43	YES
	Claims	NO
Industrial Applicability (IA)	Claims 1-43	YES
	Claims	NO

2. CITATIONS AND EXPLANATIONS

I Documents

The following documents have been considered for the purposes of this report:

D1:WO-A-93/04174 [The University of Melbourne]
D2:Clin.Exp.Allergy **22:491-497** [Klysner et al. 1992]

II Novelty

D1 discloses in figure 3 the complete nucleic acid sequence of the **Lol p V** gene and the amino acid sequence of the peptide. In figure 4, two large fragments, 2P [bp 1-559] and 1H [bp 562-1243] are disclosed, which have been expressed as GST fusion proteins in E.coli [see page 53 in D1]. However **Lol p V** peptides with a length of less than 100 amino acids have not been disclosed in D1. Hence, the subject-matter of claims 1-43 is regarded to be novel within the meaning of Article 33(2) PCT.

III Inventive step

1. D1 is the closest prior art with respect to the inventivity of the subject-matter in claims 1-43. D1 discloses 2 allergenic isoforms of **Lol p V** (designated as **Lol p Ib**) and in a test on 30 ryegrass pollen sensitive patients, 80% possessed specific IgE binding to those isoforms. The problem to be solved by the present application with respect to D1 is the provision of further agents for the detection or treatment of sensitivity to ryegrass pollen.

2. This problem has been solved by the Applicants by preparing a large number of petides derived from **Lol p V** which are capable to stimulate T cells from sensitive individuals, indicating the presence of a T cell epitope. Such small peptides have not been disclosed nor suggested and the presence of an inventive step within the meaning of Article 33(3) PCT can therefore be acknowledged.

VI. Certain documents cited

1.Certain published documents (Rule 70.10)

Application No. Patent No.	Publication Date (day/month/year)	Filing Date (day/month/year)	Priority date (valid claim) (day/month/year)
WO-A-94/04564	03.03.94	13.08.93	14.08.92

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 5, 14 and 15 concern peptides which, when administered to an allergic individual, induces T cells to become nonresponsive or modify the lymphokine secretion profile of T cells in the individual. The claims attempt to define features of the invention, by a result to be achieved, whereas it is well possible to characterise the features in a more precise way, such as by using the sequence of the claimed peptides. Consequently, claims 5, 14 and 15 are regarded not to be clear within the meaning of Article 6 PCT.

Claims

What is claimed is:

1. An isolated peptide of *Lol p* V wherein said peptide comprises at least one T cell epitope of *Lol p* V, said peptide having at least 7, but no more than 100, amino acid residues comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in Fig. 2 of peptides LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

2. An isolated peptide of claim 1, said peptide having at least 7, but no more than 10, amino acid residues comprising an amino acid sequence selected from the group consisting of the amino acid sequences as shown in Fig. 2 of peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28).

3. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index of at least 2.0.

4. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index approximately equivalent to or greater than the T cell stimulation index of said isolated peptide from which it is derived.

5. An isolated peptide of claim 1 which, when administered to an individual sensitive to *Lol p* V allergen, induces T cells to become nonresponsive or modifies the lymphokine secretion profile of T cells in the individual.

PATENT COOPERATION TREA[illegible]

DOCKETED
Aug 19, 1995 -
First Written opinion

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:
MANDRAGOURAS, Amy, E.
Lahive & Cockfield
60 State Street
Boston, MA 02109
ETATS-UNIS D'AMERIQUE

RECEIVED
LAHIVE & COCKFIELD
MAY 26 1995
BY TC

WRITTEN OPINION

(PCT Rule 66)

Date of mailing *(day/month/year)*	19.05.95
Applicant's or agent's file reference: IMI-040CP2PC	REPLY DUE within 3 months/~~days~~ from the above date of mailing

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US 94/09024	05/08/1994	13/08/1993

International Patent Classification (IPC) or both national classification and IPC
C12N15/29

Applicant
IMMULOGIC PHARMACEUTICAL CORPORATION et al.

1. This written opinion is the first (first, etc.) drawn up by this International Preliminary Examining Authority.

2. This report contains indications and corresponding pages relating to the following items:

- I [X] Basis of the opinion
- II [ ] Priority
- III [X] Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV [ ] Lack of unity of invention
- V [X] Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI [X] Certain documents cited
- VII [ ] Certain defects in the international application
- VIII [X] Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4*bis*.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 13/12/1995.

Name and mailing address of the IPEA
European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk - Netherlands
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer
Examiner M. Cupido

Formalities officer
(incl. extension of time limits) E. Reisinger
Telephone No.

I. Basis of the opinion

1. This opinion has been drawn up on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".):

[X] the international application as originally filed.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step, or to be industrially applicable have not been and will not be examined in respect of:

[X] claims 44-48

because:

[X] no international search report has been established for claims 44-48.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims 1-21, 23-28 and 37-43.
Inventive Step (IS)	Claims 22 and 29-36

2. CITATIONS AND EXPLANATIONS

I Documents

The following documents are referred to in this opinion; the numbering will be adhered to in the rest of the procedure:

D1:WO-A-93/04174 [The University of Melbourne]
D2:Clin.Exp.Allergy **22:491-497** [Klysner et al. 1992]

II Novelty

1. D1 discloses in figure 3 the complete nucleic acid sequence of the **Lol p V** gene and the amino acid sequence of the peptide. In figure 4two large fragments, 2P [bp 1-559] and 1H [bp562-1243] are disclosed, which have been expressed as GST fusion proteins in **E.coli** [see page 53 in D1]. Consequently peptides **comprising** the amino acid sequences shown in figure 2 of the present application are known in the prior art. Monoclonal antibodies specific for these fragments have been disclosed in example 8 of D1. D1 also discloses diagnostic methods using **Lol p V** peptides in the claims. Hence, the subject-matter of claims 1-21, 23-28 and 37-43 is regarded to lack novelty within the meaning of Article 33(2) PCT.

2. The sequences LIX-1, LIX-1.1 and LIX-2, which contain hydroxy-proline instead of proline have not been disclosed in the prior art.

III Inventive step

D2 is the closest prior art with respect to the inventivity of peptides LIX-1, LIX-1.1 and LIX-2, which contain hydroxyproline instead of proline. D2 mentions that the presence of hydroxyproline at the NH_2-terminal sequence is a common trait of the group V allergens in grass pollen. Therefore it is not surprising to the skilled person

that variants of **Lol p V** can be isolated where the 5 proline residues at the N-terminus are found to be hydoxyprolines. Thus it is concluded that these sequences cannot be regarded as inventive within the meaning of Article 33(3) PCT.

D1 is regarded as the closest prior art with regard to the inventivity of the subject-matter of claims 22 and 29-36. These claims relate to compositions comprising a combination of peptides of which at least one is derived from **Lol p V**. The subject-matter of these claims is regarded as an obvious and consequently non-inventive combination of features as the invention consists merely in the association of peptides each functioning in its normal way and not producing any non-obvious working interrelationship.

VI. Certain documents cited

1.Certain published documents (Rule 70.10)

Application No. Patent No.	Publication Date (day/month/year)	Filing Date (day/month/year)	Priority date (valid claim) (day/month/year)
WO-A-94/04564	03.03.94	13.08.93	14.08.92

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

1. Claim 5 concerns a peptide which, when administered to an allergic individual, induces T cells to become nonresponsive or modify the lymphokine secretion profile of T cells in the individual. Whether the peptides of the present invention posses such properties **in vivo**, has not been disclosed in the application and claim 5 is regarded not to be fully supported by the description as required by Article 6 PCT.

2. The same objection is made with regard to claims 14 and 15 which also refer to peptides with specific **in vivo** capacities. As only **in vitro** results are presented in the application these claims are considered to lack support of a technical nature by the description.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/29, A61K 39/36, C07K 14/415, 16/16 — A3

(11) International Publication Number: WO 95/06728

(43) International Publication Date: 9 March 1995 (09.03.95)

(21) International Application Number: PCT/US94/09024

(22) International Filing Date: 5 August 1994 (05.08.94)

(30) Priority Data:
08/106,016 — 13 August 1993 (13.08.93) — US

(60) Parent Application or Grant
(63) Related by Continuation
US — 08/106,016 (CIP)
Filed on — 13 August 1993 (13.08.93)

(71) Applicant *(for all designated States except US)*: IMMULOGIC PHARMACEUTICAL CORPORATION [US/US]; 610 Lincoln Street, Waltham, MA 02154 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GRIFFITH, Irwin, J. [US/US]; 13 Southwick Road, North Reading, MA 01864 (US). KUO, Mei-chang [US/US]; 5 Cox.Road, Winchester, MA 01890 (US). LUQMAN, Mohammad [IN/US]; 13 Carriage Drive, Acton, MA 01720 (US).

(74) Agents: STACEY, L., Channing et al.; Immulogic Pharmaceutical Corporation, 610 Lincoln Street, Waltham, MA 02154 (US).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
4 May 1995 (04.05.95)

(54) Title: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

(57) Abstract

The present invention provides isolated peptides of *Lol p*V, a major protein allergen of the species *Lolium perenne*. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of *Lol p*V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties or other desirable properties as the corresponding, naturally-occurring allergen or portion thereof. The invention further provides nucleic acid sequences coding for peptides of the invention. Use of the therapeutic compositions comprising one or more peptides of the invention in the manufacture of medicaments for treating sensitivity to *Lol p*V or an allergen immunologically related to *Lol p*V, or for general ryegrass sensitivity in an individual, is also provided. The invention also provides nucleic acid sequence coding for *Dac g*V protein allergen as well as the amino acid sequence of *Dac g*V protein allergen.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9304174	04-03-93	AU-B-	651728	28-07-94
		AU-A-	2440992	16-03-93
		CA-A-	2115579	04-03-93
		JP-T-	6509941	10-11-94
WO-A-9404564	03-03-94	AU-B-	4691693	15-03-94
		FI-A-	950602	10-02-95

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 94/09024

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.- claims 1-43: Lol p V peptides, recombinant DNA constructs for their preparation, monoclonal antibodies and peptide mixtures.
2.- claims 44-48: Dac g V protein (referred to as Dac g I, which is assumed to be an error) and recombinant DNA constructs.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-43

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,94 04564 (THE UNIVERSITY OF MELBOURNE) 3 March 1994 see the whole document	1-43

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 94/09024

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/29 A61K39/36 C07K14/415 C07K16/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ✓	WO,A,93 04174 (THE UNIVERSITY OF MELBOURNE) 4 March 1993 see figures 3,4; examples 4,5 ---	1-43
X ✓	CLINICAL AND EXPERIMENTAL ALLERGY, vol.22, no.4, April 1992, OXFORD GB pages 491 - 497 KLYSNER ET AL. 'Group V allergens in grass pollens:IV.Similarities in amino acid compositions and NH2-terminal sequences of the Group V allergenes from Lolium perenne, Poa pratensis and Dactylis glomerata' cited in the application see the summary --- -/--	1,29,42

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 December 1994	04.04.95

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	CUPIDO, M

Form PCT/ISA/210 (second sheet) (July 1992)

LAHIVE & COCKFIELD

JOHN A. LAHIVE, JR.
W. HUGO LIEPMANN
JAMES E. COCKFIELD
THOMAS V. SMURZYNSKI
RALPH A. LOREN
THOMAS J. ENGELLENNER
WILLIAM C. GEARY III
DAVID J. POWSNER
GIULIO A. DeCONTI, JR.
MICHAEL I. FALKOFF
ANN LAMPORT HAMMITTE
JOHN V. BIANCO
AMY BAKER MANDRAGOURAS
ELIZABETH A. HANLEY
ANTHONY A. LAURENTANO
PAUL LOUIS MYERS, Ph. D.

COUNSELLORS AT LAW
SIXTY STATE STREET
BOSTON, MASSACHUSETTS 02109-1875

TELEPHONE (617) 227-7400
TELEX 752806
FAX (617) 227-5941

JANE E. REMILLARD
EDWARD J. KELLY
MARK A. KURISKO
BETH E. ARNOLD
JEAN M. SILVERI

OF COUNSEL
JEREMIAH LYNCH

PATENT AGENT
MATTHEW P. VINCENT, Ph. D.

TECHNICAL SPECIALISTS
CATHERINE J. KARA, Ph. D.
MARK D. RUSSETT
CAROLYN G. d'AGINCOURT
ISABELLE M. CLAUSS, Ph. D.
IVANA M. MAGOVCEVIC, Ph. D.

April 10, 1995

BY TELECOPIER

International Searching Authority
European Patent Office
P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
NETHERLANDS

Authorized Officer: G.L.M. Kruydenberg

RE: International Patent Application No.: PCT/US94/09024
International Filing Date: 05 August 1994
Applicant: Immulogic Pharmaceutical Corporation
Title: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN
Our Reference No: 075.1 PCT (IMI-0040CP2PC)

Dear Sirs:

In response to an Invitation to Correct Defects in the Demand mailed on March 31, 1995, Applicants enclose herewith a copy of a General Power of Attorney, giving each appointed person the authority to prosecute the above-identified PCT application. A copy of this General Power of Attorney was previously filed in the above-identified PCT application in the European Patent Office on January 10, 1995.

Respectfully submitted,

Amy E. Mandragouras
Attorney for Applicant

Enclosures

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s) :
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

IMMULOGIC PHARMACEUTICAL CORPORATION
610 Lincoln Street
Waltham, Massachusetts 02154
United States of America

hereby appoint(s) the following person as: [X] agent [ ] common representative

Name and address
(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

DECONTI, Giulio A., Jr.
MANDRAGOURAS, Amy E.
HANLEY, Elizabeth A.
MYERS, Paul Louis
LAHIVE & COCKFIELD
60 State Street
Boston, Massachusetts 02109
United States of America

CHANNING, Stacey L.
VANSTONE, Darlene A.
YANKWICH, Leon R.
IMMULOGIC PHARMACEUTICAL CORPORATION
610 Lincoln Street
Waltham, Massachusetts 02154
United States of America

to represent the undersigned before

[X] all the competent International Authorities

[ ] the International Searching Authority only

[ ] the International Preliminary Examining Authority only

in connection with any and all international applications filed by the undersigned with the following Office

_____ as receiving Office

and to make or receive payments on behalf of the undersigned.

Signature(s) *(where there are several persons, each of them must sign; next to each signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading this power)*:

IMMULOGIC PHARMACEUTICAL CORPORATION

Stacey L Channing / Corporate Secretary
Stacey L. Channing, Secretary

Date: 10/19/93

Form PCT/Model of general power of attorney (for several international applications) (July 1992)

PATENT COOPERATION TREATY

ENTERED DOCKETED April 30, 1995 - Correct Defects

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:
MANDRAGOURAS, Amy, E.
Lahive & Cockfield
60 State Street
Boston, MA 02109
ETATS-UNIS D'AMERIQUE

RECEIVED
LAHIVE & COCKFIELD
APR 0 6 1995
BY TC

INVITATION TO CORRECT DEFECTS IN THE DEMAND

(PCT Rule 60.1)

	Date of mailing *(day/month/year)* 31.03.95
Applicant's or agent's file reference IMI-040CP2PC	**REPLY DUE** within **ONE MONTH** from the above date of mailing. See also below.
International application No. PCT/US 94/09024	International filing date *(day/month/year)* 05/08/1994
Applicant IMMULOGIC PHARMACEUTICAL CORPORATION et al.	

The applicant is hereby **invited** within the time limit indicated above **to correct the following defects** which this International Preliminary Examining Authority has found in the demand for international preliminary examination:

1. ☐ It does not contain the election of at least one Contracting State bound by Chapter II (Rules 53.2(a)(iv) and 53.7).
2. ☐ It does not permit identification of the international application to which it relates (Rule 60.1(b)).
3. ☐ It does not contain the required petition (Rules 53.2(a)(i) and 53.3).
4. ☐ It does not contain the required indications concerning the agent as specified in the Annex (Rules 53.2(a)(ii) and 53.5).
5. ☐ It does not contain the required indications concerning the international application as specified in the Annex (Rules 53.2(a)(iii) and 53.6).
6. ☐ It is not submitted in the required language which is: _____ (Rule 55.1).
7. ☐ It is not made on the printed form (rule 53.1(a)).
8. ☐ It is presented as a computer print-out the particulars of which do not comply with the Administrative Instructions (Rule 53.1(a)).
9. ☐ It does not contain the required indications concerning the applicant as specified in the Annex (Rules 53.2(a)(ii) and 53.4).
10. ☒ It does not contain the required signature as specified in the Annex (Rules 53.2(b) and 53.8).

Effects of the date of receipt of the corrections on the date of receipt of the demand:

(i) If the defects noted under items 1 and 2 are corrected within the time limit indicated above, the demand will be considered to have been received on the date when the corrections are received (Rule 60.1(b)). If that date is later than the expiration of 19 months from the priority date, entry into the national phase before the elected Offices will **NOT** be postponed until the expiration of 30 months from the priority date.

(ii) If the defects noted under items 3 to 10 are corrected within the time limit indicated above, the demand will be considered to have been received on its actual filing date (Rule 60.1(b)).

Effects of failure to correct the defects within the time limit indicated above:

(i) In the case of defects noted under items 1 to 8, the demand will be considered as not having been submitted.

(ii) In the case of defects noted under items 9 and 10, the election(s) of the State(s) concerned will be considered as not having been made.

A copy of this invitation has been sent to the International Bureau.

Name and mailing address of the IPEA European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Netherlands Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer G.L.M. Kruydenberg Telephone No.

INVITATION TO CORRECT DEFECTS IN THE DEMAND

International application No.
PCT/US 94/09024

Continuation of item 4: As to indications concerning **the agent** (Rule 4.4), the demand:

a. ☐ does not properly indicate the agent's name *(specify)*:

b. ☐ does not indicate the agent's address.

c. ☐ does not properly indicate the agent's address *(specify)*:

Continuation of item 5: As to indications concerning **the international application,** the demand does not indicate:

a. ☐ the international filing date.

b. ☐ the international application number.

c. ☐ the name of the receiving Office, where the international application number was not known to the applicant at the time the demand was filed.

d. ☐ the title of the invention.

Continuation of item 9: As to indications concerning **the applicant** (Rules 4.4 and 4.5), the demand:

a. ☐ does not indicate all the applicants for the elected States.

b. ☐ does not properly indicate the applicant's name *(specify)*:

c. ☐ does not indicate the applicant's address.

d. ☐ does not properly indicate the applicant's address *(specify)*:

e. ☐ does not indicate the applicant's nationality.

f. ☐ does not indicate the applicant's residence.

Continuation of item 10: As to indications concerning **signature** (Rules 4.15 and 90.4), the demand:

a. ☐ is not signed.

b. ☐ is not signed by all the applicants for the elected States.

c. ☐ is not accompanied by the statement referred to in the check list in Box No. VI of the demand explaining the lack of the signature of an applicant for the election of the United States of America.

d. ☒ is signed by what appears to be an agent/common representative but

☒ the demand is not accompanied by a power of attorney appointing him.

☐ the power of attorney accompanying the demand is not signed by all the applicants for the elected States.

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ EP

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty.

For International Preliminary Examining Authority use only

Identification of IPEA	Date of receipt of DEMAND

Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION

International application No.	International filing date *(day/month/year)*	Applicant's or agent's file reference / (Earliest) Priority date *(day/month/year)*
PCT/US94/09024	05 August 1994 (05.08.94)	IMI-040CP2PC (075.1PCT) / 13 August 1993 (13.08.93)

Title of invention

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

Box No. II APPLICANT(S)

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

IMMULOGIC PHARMACEUTICAL CORPORATION
610 Lincoln Street
Waltham, Massachusetts 02154
United States of America

Telephone No.:

Facsimile No.:

Teleprinter No.:

State *(i.e. country)* of nationality: United States of America

State *(i.e. country)* of residence: United States of America

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

GRIFFITH, Irwin J.
13 Southwick Road
North Reading, Massachusetts 01864
United States of America

State *(i.e. country)* of nationality: United States of America

State *(i.e. country)* of residence: United States of America

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

KUO, Mei-chang
5 Cox Road
Winchester, Massachusetts 01890
United States of America

State *(i.e. country)* of nationality: United States of America

State *(i.e. country)* of residence: United States of America

[X] Further applicants are indicated on a continuation sheet.

Sheet No. 2

International application No. PCT/US94/09024

Continuation of Box No. II APPLICANT(S)

If none of the following sub-boxes is used, this sheet is not to be included in the demand.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

LUQMAN, Mohammad
13 Carriage Drive
Acton, Massachusetts 01720
United States of America

State *(i.e. country)* of nationality:	State *(i.e. country)* of residence:
India	United States of America

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

State *(i.e. country)* of nationality:	State *(i.e. country)* of residence:

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

State *(i.e. country)* of nationality:	State *(i.e. country)* of residence:

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

State *(i.e. country)* of nationality:	State *(i.e. country)* of residence:

☐ Further applicants are indicated on another continuation sheet.

International application No.
PCT/US94/09024

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person is [X] agent [ ] common representative

and [X] has been appointed earlier and represents the applicant(s) also for international preliminary examination.

[ ] is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.

[ ] is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

MANDRAGOURAS, Amy E.
Lahive & Cockfield
60 State Street
Boston, Massachusetts 02109
United States of America

Telephone No.:

Facsimile No.:

Teleprinter No.:

[ ] Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV STATEMENT CONCERNING AMENDMENTS

The applicant wishes the International Preliminary Examining Authority*

(i) [X] to start the international preliminary examination on the basis of the international application as originally filed.

(ii) [ ] to take into account the amendments under Article 34 of

- [ ] the description (amendments attached).
- [ ] the claims (amendments attached).
- [ ] the drawings (amendments attached).

(iii) [ ] to take into account any amendments of the claims under Article 19 filed with the International Bureau (a copy is attached).

(iv) [ ] to disregard any amendments of the claims made under Article 19 and to consider them as reversed.

(v) [ ] to postpone the start of the international preliminary examination until the expiration of 20 months from the priority date unless that Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). *(This check-box may be marked only where the time limit under Article 19 has not yet expired.)*

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Box No. V ELECTION OF STATES

[X] The applicant hereby elects all eligible States *(that is, all States which have been designated and which are bound by Chapter II of the PCT)* except .....

(If the applicant does not wish to elect certain eligible States, the name(s) or country code(s) of those States must be indicated above.)

International application No.
PCT/US94/09024

Box No. VI CHECK LIST

The demand is accompanied by the following documents for the purposes of international preliminary examination:			For International Preliminary Examining Authority use only: received	not received
1. amendments under Article 34				
description	:	sheets	☐	☐
claims	:	sheets	☐	☐
drawings	:	sheets	☐	☐
2. letter accompanying amendments under Article 34	:	sheets	☐	☐
3. copy of amendments under Article 19	:	sheets	☐	☐
4. copy of statement under Article 19	:	sheets	☐	☐
5. other *(specify)*:	:	sheets	☐	☐

The demand is also accompanied by the item(s) marked below:

1. ☐ separate signed power of attorney
2. ☐ copy of general power of attorney
3. ☐ statement explaining lack of signature
4. ☒ fee calculation sheet
5. ☒ other *(specify)*: Transmittal Letter, EPA/EPO/OEB Form 1037.1 and Bank Draft

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

Amy E. Mandragouras

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:
2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):
3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. ☐ The applicant has been informed accordingly.
4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.
5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

See Notes to the demand form

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference *(12 character maximum)*:
075.1 PCT

Box No. 1 TITLE OF INVENTION

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

Box No. II APPLICANT

Name and address:

IMMULOGIC PHARMACEUTICAL CORPORATION
610 Lincoln Street
Waltham, MA 02154
United States of America

[ ] This person is also inventor.

Telephone No: 617-466-6000

Facsimile No: 617-466-6040

Teleprinter No:

State of nationality: United States of America

State of residence: United States of America

Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

Name and address:

GRIFFITH, Irwin J.
13 Southwick Road
North Reading, Massachusetts 01864
United States of America

This person is:

[ ] applicant only

[x] applicant and inventor

[ ] inventor only (if this box is marked, do not fill in below)

State of nationality: US

State of residence: US

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States except the United States of America [X] the United States of America only [ ] the States indicated in the Supplemental Box

Name and address:

KUO, Mei-chang
5 Cox Road
Winchester, Massachusetts 01890
United States of America

This person is:

[ ] applicant only

[x] applicant and inventor

[ ] inventor only (if this box is marked, do not fill in below)

State of nationality: US

State of residence: US

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States except the United States of America [X] the United States of America only [ ] the States indicated in the Supplemental Box

[X] Further applicants and/or (further) inventors are indicated on a continuation sheet

Sheet No. 2

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

Name and address:	This person is:
LUQMAN, Mohammad 13 Carriage Drive Acton, Massachusetts 01720 United States of America	[ ] applicant only [x] applicant and inventor [ ] inventor only (if this box is marked, do not fill in below)
State of nationality: India	State of residence: US

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States States except the United States of America [X] the United States of America only [ ] the States indicated in the Supplemental Box

Name and address:	This person is:
	[ ] applicant only [ ] applicant and inventor [ ] inventor only (if this box is marked, do not fill in below)
State of nationality:	State of residence:

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States States except the United States of America [ ] the United States of America only [ ] the States indicated in the Supplemental Box

Name and address:	This person is:
	[ ] applicant only [ ] applicant and inventor [ ] inventor only (if this box is marked, do not fill in below)
State of nationality:	State of residence:

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States States except the United States of America [ ] the United States of America only [ ] the States indicated in the Supplemental Box

Name and address:	This person is:
	[ ] applicant only [ ] applicant and inventor [ ] inventor only (if this box is marked, do not fill in below)
State of nationality:	State of residence:

This person is applicant for the purposes of: [ ] All designated States [ ] All designated States States except the United States of America [ ] the United States of America only [ ] the States indicated in the Supplemental Box

[ ] Further applicants and/or (further) inventors are indicated on another continuation sheet

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESSEE FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: [X] agent [ ] common representative

Name and address:

Stacey L. Channing
Darlene A. Vanstone
Anne I. Craig
IMMULOGIC PHARMACEUTICAL CORPORATION
610 Lincoln Street
Waltham, MA 02154
United States of America

Telephone No: 617-466-6000

Facsimile No: 617-466-6040

Teleprinter No:

[ ] Mark this check box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address

Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a)

Regional Patent

[X] **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT

[X] **OA OAPI Patent:** Benin, Burkina Faso, Cameroon, Central AFrican Republic, Chad, Congo, Côte d'Ivoire, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT

National Patents *(if other kind of protection desired, specify)*:

[X] AT Austria
[X] AU Australia
[X] BB Barbados
[X] BG Bulgaria
[X] BR Brazil
[X] BY Belarus
[X] CA Canada
[X] CH and LI Switzerland and Liechtenstein
[X] CN China
[X] CZ Czech Republic
[X] DE Germany
[X] DK Denmark
[X] ES Spain
[X] FI Finland
[X] GB United Kingdom
[X] HU Hungary
[X] JP Japan
[X] KP Democratic People's Republic of Korea
[X] KR Republic of Korea
[X] KZ Kazakhstan
[X] LK Sri Lanka
[X] LU Luxembourg
[X] LV Latvia
[X] MG Madagascar
[X] MN Mongolia
[X] MW Malawi
[X] NL Netherlands
[X] NO Norway
[X] NZ New Zealand
[X] PL Poland
[X] PT Portugal
[X] RO Romania
[X] RU Russian Federation
[X] SD Sudan
[X] SE Sweden
[X] SK Slovakia
[X] UA Ukraine
[X] US United States of America - a CIP of 08/106,016
[X] UZ Uzbekistan
[X] VN Viet Nam

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

[ ]
[ ]

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of _____.
The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.

For 3½" Disk

Pull Tab to Open

DENNISON

Disk Mailer

From

LAHIVE & COCKFIELD
60 State Street
Boston, MA 02109

To

SEQUENCE LISTING UNDER PCT RULES 5&13

Applicant: ImmuLogic Pharmaceutical Corporation

Serial No.: (from PCT/US94/09024)

Filed: Herewith

For: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

Copy: JAPAN NATIONAL FILING

Docket No.: IMI-040C2JP Date: 1/18/96

3.5" Diskette, 720 K MS-DOS 5.0

Handle With Care

ROPERTY ORGANIZATION
al Bureau

075.1 PCT

...DER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/29, A61K 39/36, C07K 14/415, 16/16	A2	(11) International Publication Number: WO 95/06728
		(43) International Publication Date: 9 March 1995 (09.03.95)

(21) International Application Number: PCT/US94/09024

(22) International Filing Date: 5 August 1994 (05.08.94)

(30) Priority Data:
08/106,016 13 August 1993 (13.08.93) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/106,016 (CIP)
Filed on 13 August 1993 (13.08.93)

(71) Applicant *(for all designated States except US)*: IMMULOGIC PHARMACEUTICAL CORPORATION [US/US]; 610 Lincoln Street, Waltham, MA 02154 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GRIFFITH, Irwin, J. [US/US]; 13 Southwick Road, North Reading, MA 01864 (US). KUO, Mei-chang [US/US]; 5 Cox Road, Winchester, MA 01890 (US). LUQMAN, Mohammad [IN/US]; 13 Carriage Drive, Acton, MA 01720 (US).

(74) Agents: STACEY, L., Channing et al.; Immulogic Pharmaceutical Corporation, 610 Lincoln Street, Waltham, MA 02154 (US).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

(57) Abstract

The present invention provides isolated peptides of *Lol p*V, a major protein allergen of the species *Lolium perenne*. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of *Lol p*V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties or other desirable properties as the corresponding, naturally-occurring allergen or portion thereof. The invention further provides nucleic acid sequences coding for peptides of the invention. Use of the therapeutic compositions comprising one or more peptides of the invention in the manufacture of medicaments for treating sensitivity to *Lol p*V or an allergen immunologically related to *Lol p*V, or for general ryegrass sensitivity in an individual, is also provided. The invention also provides nucleic acid sequence coding for *Dac g*V protein allergen as well as the amino acid sequence of *Dac g*V protein allergen.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgystan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LI	Liechtenstein
LK	Sri Lanka
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SI	Slovenia
SK	Slovakia
SN	Senegal
TD	Chad
TG	Togo
TJ	Tajikistan
TT	Trinidad and Tobago
UA	Ukraine
US	United States of America
UZ	Uzbekistan
VN	Viet Nam

T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

Background of the Invention:

Allergens constitute the most abundant proteins of grass pollen, which is the major cause of allergic disease in temperate climates (Marsh (1975) Allergens and the genetics of allergy; in M. Sela (ed.), The Antigens, Vol. 3, pp 271-359, Academic Press Inc., London, New York)., Hill et al. (1979) *Medical Journal of Australia,* 1:426-429). The first descriptions of the allergenic proteins in ryegrass showed that they are immunochemically distinct, and are known as groups I, II, III and IV (Johnson and Marsh (1965) *Nature*, 206:935-942; and Johnson and Marsh (1966) *Immunochemistry,* 3:91-100). Using the International Union of Immunological Societies' (IUIS) nomenclature, these allergens are designated *Lol p* I, *Lol p* II, *Lol p* III and *Lol p* IV. In addition, another important *Lolium perenne L.* allergen that has been identified in the literature is *Lol p IX* which is also known as *Lol p* V or *Lol p* Ib (Singh et al. (1991) *Proc. Natl. Acad. Sci, USA,* 88:1384-1388).

These five proteins have been identified in pollen ryegrass, *Lolium perenne* L., and act as antigens in triggering immediate (Type 1) hypersensitivity in susceptible humans.

Lol p V is defined as an allergen because of its ability to bind to specific IgE in sera of ryegrass-sensitive patients, to act as an antigen in IgG responses and to trigger T-cell responses. The allergenic properties have been demonstrated by immunoblotting studies showing 80% of ryegrass pollen sensitive patients possessed specific IgE antibody that bound to *Lol p* V isoforms (PCT application publication number WO 93/04174, page 65). These results indicate that *Lol p* V is a major ryegrass allergen.

Substantial allergenic cross-reactivity between grass pollens has been demonstrated using an IgE-binding assay, the radioallergo-sorbent test (RAST), for example, as described by Marsh et al. (1970) J. Allergy, 46, 107-121, and Lowenstein (1978) Prog. Allergy, 25, 1-62. (Karger, Basel).

The immunochemical relationship of *Lol p* V with other grass pollen antigens have been demonstrated using both polyclonal and monoclonal antibodies (Zhang et al., *Int. Arch Allergy Appl Immunol*, 96:28-34 (1991); Roberts et al., *Int. Arch Allergy Appl Immunol*, 98:178-180 (1992); Mattheisen and Lowenstein, *Clinical and Experimental Allergy*, 21:309-320 (1991); and van Ree et al., *J. Allergy Clin. Immunol.* 83:144-151

(1989)). Antibodies have been prepared to purified proteins that bind IgE components. These data demonstrate that a major allergen is present in pollen of closely related grasses is immunochemically similar to *Lol p* V and are generally characterized as Group V allergens.

In view of the prevalence of ryegrass pollen allergens and related grass allergens all over the world, there is a pressing need for the development of compositions and methods that could be used in detecting sensitivities to *Lol p* V or other immunologically related grass allergens, or in treating sensitivities to such allergens, or in assisting in the manufacture of medicaments to treat such sensitivities. The present invention provides materials and methods having one or more of those utilities.

Summary of the Invention

The present invention provides isolated peptides of *Lol p* V. Peptides within the scope of the invention comprise at least one T cell epitope, preferably at least two T cell epitopes of *Lol p* V. The invention further provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p* V.

The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects, as well as modified peptides having improved properties such as increased solubility and stability. Therapeutic peptides of the invention are capable of modifying, in a *Lol p* V-sensitive individual to whom they are administered, the allergic response of the individual to *Lol p* V or an allergen immunologically cross-reactive *Lol p* V e.g. allergens derived from pollen belonging to the Poacea (Graminae) family such as *Dactylis glomerata*, *Dac g* V.

Methods of treatment or of diagnosis of sensitivity to ryegrass pollen protein, *Lol p* V in an individual or to pollen proteins that are immunologically related to *Lol p* V such as *Dac g* V, and therapeutic compositions comprising one or more peptides of the invention are also provided.

The present invention also provides nucleic and amino acid sequences of *Dac g* V protein allergen which is immunologically cross-reative with *Lol p* V.

Further features of the present invention will be better understood from the following detailed description of the preferred embodiments of the invention in conjunction with the appended figures.

Brief Description of the Figures

Fig. 1 shows the nucleotide sequence of cDNA clone 12R (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2). Clone 12R is a full-length clone of *Lol p* V derived from a λgtII library (see PCT application publication number WO93/04174).

Fig. 2 shows peptides of the invention of various lengths derived from *Lol p V* (SEQ ID NO:3-29).

Fig. 3 shows peptides of various lengths derived from *Lol p* I (SEQ ID NO:30-53).

Fig. 4 is a graphic representation depicting the response of T cell lines from 19 patients primed *in vitro* with affinity purified *Lol p* V and analyzed for response to *Lol p* V peptides (derived from the *Lol p* V protein allergen) by percent of responses with a mean S.I. of at least 2 (indicated above each bar), the numbers enclosed in the parenthesis denote percentage of patients responding to the particular peptide, and the bar represents the positivity index for each peptide (% of patients responding multiplied by the mean S.I.).

Fig. 5 is a graphic representation derived from the same data shown in Fig. 4 showing the ranked sum for each peptide, the bar represents the cumulative rank of the peptide response in the group of 19 patients tested, above each bar in parenthesis is the percent of patients positively responding to each peptide, the S.I. is also indicated above each bar.

Fig. 6 is a graphic representation of the results of a direct ELISA, the source of IgE was a sample of pooled human plasma (PHP) designated PHP-A, and wherein the antigen is either soluble pollen extract (SPE) of ryegrass pollen, or bacterially expressed recombinant Lol p V (rLolpV).

Fig. 7 is a graphic representation of the results of a direct ELISA, the source of IgE was a sample of pooled human plasma (PHP) designated PHP-B and wherein the antigen is either soluble pollen extract (SPE) of ryegrass pollen, r*Lol p*V.

Fig. 8 is a graphic representation of the results of a direct ELISA, the source of IgE was plasma from 4 individual patients, #1118, #1120, #1125, #1141, and wherein the antigen is ryegrass pollen SPE.

Fig. 9 is a graphic representation of the results of a direct ELISA the source of IgE was plasma from 4 individual patients, #1118, #1120, #1125, #1141, and wherein the antigen is r*Lol p* V.

Fig. 10 is a graphic representation of the results of a competition ELISA, the source of IgE was a sample of pooled human plasma designated PHP-A, IgE binding was measured in the presence of ryegrass pollen SPE, affinity purified native *Lol p* V or r*Lol p* V.

Fig. 11 is a graphic representation of the results of a competition ELISA, the source of IgE was plasma from individual patient #706 as a source of IgE, IgE binding was measured in the presence of ryegrass pollen SPE, affinity purified Lol p V or rLol p V.

Fig. 12 is a graphic representation of a histamine release assay to ryegrass pollen SPE and r*Lol p* V.

Fig. 13a and Fig. 13b each show a graphic representation of a direct ELISA using a sample of pooled human plasma designated PHP-B as a source of IgE, and wherein the antigen was either a selected peptide derived from *Lol* p V or r*Lol p* V.

Fig. 14 is a graphic representation of a competition ELISA using a sample of pooled human plasma designated PHP-B as a source of IgE, and wherein the antigens were a mixture of affinity purified *Lol p* I and *Lol p* V or a mixture of recombinant *Lol p* I (r*Lol p* I) or r*Lol p* V to compete for IgE binding to ryegrass pollen SPE.

Fig. 15 is a photograph of a Coomassie blue stained SDS-PAGE (12.5%) analysis of an Ab1B9-affinity purified native *Lol p* V, the sample was run under reducing conditions. the molecular weight standards are shown on the left.

Fig. 16 shows the nucleotide sequence of clone 259 of *Dac g* V, and its predicted amino acid sequence, the nucleotide sequence of nucleotides 1 to 699 has been confirmed, and the nucleotide sequence of nucleotides 700 to 1181 are unconfirmed.

Detailed Description of the Invention

The present invention provides isolated peptides derived from *Lol p* V. The present invention also provides *Dac g* V protein allergen which is immunologically cross-reactive with *Lol p* V. As used herein, a "peptide" refers to any protein fragment of *Lol p* V that induces an immune response. The terms "fragment and "antigenic fragment" as used herein refer to an amino acid sequence having fewer amino acid residues than the entire amino acid sequence of the protein from which the fragment is derived, and that induces an immune response. The terms "isolated" and "purified" as used herein refer to peptides of the invention which are substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when synthesized chemically. As used herein, the term "peptide" of the invention include peptides derived from *Lol p* V which comprise at least one T cell epitope of the allergen or a portion of such peptide which comprises at least one T cell epitope.

Peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p* V are also within the scope of the invention. Isolated peptides or regions of isolated peptides, each comprising at least two T cell epitopes of *Lol p* V protein allergen are particularly desirable for increased therapeutic effectiveness. Peptides which are immunologically related (e.g., by antibody or T cell cross-reactivity) to peptides of the present invention, such as peptides from *Dac g* V, are also within the scope of the invention. Peptides immunologically related by antibody cross-reactivity, are bound by antibodies specific for a peptide of *Lol p* V. Peptides immunologically related by T cell cross-reactivity are capable of reacting with the same T cells as a peptide of the invention.

Isolated peptides of the invention can be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid having a sequence encoding such peptide. The isolated peptides of the invention can also be produced by chemical synthesis. When a peptide is produced by recombinant techniques, host cells transformed with a nucleic acid having a sequence encoding a peptide of the invention or the functional equivalent of the nucleic acid sequence are cultured in a medium suitable for the cells and peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis or immunopurification with antibodies specific for the peptide, the protein allergen from which the peptide is derived, or a portion thereof.

The present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention. Nucleic acid coding for a *Lol p* V peptide of the invention or at least one fragment thereof may be expressed in bacterial cells such as *E. coli*, insect cells, yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art. Suitable vectors for expression in yeast include YepSec1 (Baldari et al. (1987) *Embo J.* 6: 229-234); pMFa (Kurjan and Herskowitz (1982) *Cell* 30: 933-943); JRY88 (Schultz et al. (1987) *Gene* 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego, CA) for

expression in insect cells while the pMSG vector is commercially available (Pharmacia, Piscataway, NJ) for expression in mammalian cells.

For expression in *E. coli*, suitable expression vectors include, among others, pTRC (Amann et al. (1988) *Gene* 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRIT5 (Pharmacia, Piscataway, NJ); pET-11d (Novagen, Madison, WI) Jameel et al., (1990) *J. Virol.* 64:3963-3966; and pSEM (Knapp et al. (1990) *BioTechniques* 8: 280-281). The use of pTRC, and pET-11d, for example, will lead to the expression of unfused protein. The use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of allergen fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated ß-galactosidase (PSEM), or glutathione S-transferase (pGEX). When a *Lol p* V peptide of the invention is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and *Lol p* V peptide. The *Lol p* V peptide may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from, for example, Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann et al., (1988) *supra*; pET-11d, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, NJ) . It may also be appropriate to express recombinant *Lol p* V peptides in different *E. coli* hosts that have an altered capacity to degrade recombinantly expressed proteins (e.g. U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic acid sequence to use codons preferentially utilized by *E. coli*, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.

Host cells can be transformed to express the nucleic acid sequences of the invention using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming the host cells may be found in Sambrook et al. *supra*, and other laboratory textbooks. The nucleic acid sequences of the invention may also be chemically synthesized using standard techniques (i.e. solid phase synthesis). Details of the isolation and cloning of clone 12R encoding *Lol p* V (described as *Lol p* Ib.1) are given in PCT application Publication Number WO 93/04174 incorporated herein by reference in its entirety.

Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene*, 69:301-315) and pET11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET11d relies on transcription from the T7 gn10-lac 0 fusion promoter mediated by coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant *Lol p* V peptide expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:119-128). Another strategy would be to alter the nucleic acid sequence of the desired gene to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed *E. coli* proteins (Wada *et al.* (1992) *Nuc. Acids Res*, 20:2111-2118). Such alteration of nucleic acid sequences of the invention could be carried out by standard DNA synthesis techniques.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura *et al.* U.S. Patent 4,598,049; Caruthers *et al.* U.S. Patent 4,458,066; and Itakura U.S. Patents 4,401,796 and 4,373,071, incorporated by reference herein).

The present invention also provides nucleic acid sequences encoding peptides of the invention. Nucleic acid sequences used in any embodiment of this invention can be cDNAs encoding corresponding peptide sequences as shown in Fig. 2 (SEQ ID NO:3-29). Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which is 1) a sequence capable of hybridizing to a complementary oligonucleotide to which the sequence (or corresponding sequence portions) of *Lol p* V as shown in Fig. 1 or fragments thereof hybridizes, or 2) the sequence (the corresponding sequence portions complementary to the nucleic acid sequences encoding the peptide sequence derived from *Lol p* V as shown in Fig. 2 and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded

by the sequence (or corresponding sequence portion) of *Lol p* V as shown in Fig. 1. Whether a functional equivalent must meet one or more criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first or second criteria and if it is to be used to produce a *Lol p V* peptide of the invention, it need only meet the third criterion). The nucleic acid sequences of the invention also include RNA which can be transcribed from the DNA prepared as described above.

Preferred nucleic acids encode a peptide having at least about 50% homology to a *Lol p* V peptide of the invention, more preferably at least about 60% homology and most preferably at least about 70% homology with a *Lol p* V peptide of the invention. Nucleic acids that encode peptides having at least about 90%, more preferably at least about 95%, and most preferably at least about 98-99% homology with *Lol p* V peptides of the invention are also within the scope of the invention. Homology refers to sequence similarity between two peptides of *Lol p* V, or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same nucleotide or amino acid, then molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences.

Preferred nucleic acid fragments encode peptides of at least 7 amino acid residues in length, and preferably 13-40 amino acid residues in length, and more preferably at least 16-30 amino acids residues in length, Nucleic acid fragments encoding peptides of at least 30 amino acid residues in length, at least 40 amino acid residues in length, at least about 80 amino acid residues in length, at least about 100 amino acid residues in length or more, are also contemplated.

Also within the scope of the invention are nucleic acid sequences encoding allergens immunologically cross-reactive with *Lol p* V, such as full length *Dac g* V protein or peptides (Fig. 16). Proteins and peptides of *Dac g* V may be produced recombinantly as discussed above, or synthetically. Expression vectors and host cells transformed to express *Dac g* V protein or peptides thereof are also within the scope of the invention. Details of the cloning of *Dac g* V are given in the examples.

The present invention also provides a method of producing isolated *Lol p* V peptides of the invention or a portion thereof comprising the steps of culturing a host cell transformed with a nucleic acid sequence encoding a *Lol p* V peptide of the invention in an appropriate medium to produce a mixture of cells and medium containing said *Lol p* V peptide; and purifying the mixture to produce substantially pure *Lol p* V peptide. Host

cells transformed with an expression vector containing DNA coding for a *Lol p* V peptide of the invention or a portion thereof are cultured in a suitable medium for the host cell. *Lol p* V peptides of the invention can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for the *Lol p* V peptides or portions thereof of the invention.

Another aspect of the present invention pertains to an antibody specifically reactive with a *Lol p* V peptide. Such antibodies may be used to standardize allergen extracts or to isolate the naturally occurring *Lol p* V. Also, Lol p V peptides of the invention can be used as "purified" allergens to standardize allergen extracts. For example, an animal such as a mouse or rabbit can be immunized with an immunogenic form of an isolated *Lol p* V peptide of the invention capable of eliciting an antibody response. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well-known in the art. The *Lol p* V peptide also can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization, anti-*Lol p* V peptide antisera can be obtained and, if desired, polyclonal anti-*Lol p* V peptide antibodies from the serum. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Hybridoma cells can be screened immunochemically for production of antibodies reactive with the *Lol p* V peptides of the invention. These sera or monoclonal antibodies can be used to standardize allergen extracts.

Through use of the peptides and antibodies of the present invention, preparations of consistent, well-defined composition and biological activity can be made and administered for therapeutic purposes (e.g. to modify the allergic response of a ryegrass pollen sensitive individual to pollen of such grasses or pollen of an immunologically related grass such as *Dac g* V). Administration of such peptides may, for example, modify B-cell response to *Lol p* V allergen, T-cell response to *Lol p* V allergen or both responses. Isolated peptides can also be used to study the mechanism of immunotherapy of ryegrass pollen allergy and to design modified derivatives or analogues useful in immunotherapy.

The present invention also pertains to T cell clones which specifically recognize *Lol p* V peptides of the invention. These T cell clones may be suitable for isolation and molecular cloning of the gene for the T cell receptor which is specifically reactive with a peptide of the present invention. The T cell clones may be produced as described in *Cellular and Molecular Immunology,* Abdul K. Abbas et al., W.B. Saunders Co. (1991) pg. 139. The present invention also pertains to soluble T cell receptors. These receptors may inhibit antigen-dependent activation of the relevant T cell subpopulation within an individual sensitive to Lol p V. Antibodies specifically reactive with such a T cell receptor can also be produced according to the techniques described herein. Such antibodies may also be useful to block T-cell -MHC interaction in an individual. Methods for producing soluble T cell receptors are described in *Immunology; A Synthesis,* 2nd Ed., Edward S. Golub et al., Sinaur Assoc, Sunderland Massachusetts, (1991) pp. 366-369.

To obtain isolated peptides of the present invention, *Lol p* V is divided into non-overlapping peptides of desired length or overlapping peptides of desired lengths as discussed in Example 2 which can be produced recombinantly, synthetically, or in certain situations, by chemical cleavage of the allergen. Peptides comprising at least one T cell epitope are capable of eliciting a T cell response, such as stimulation (i.e. proliferation or lymphokine secretion) and/or are capable of inducing T cell non-responsiveness. To determine peptides comprising at least one T cell epitope, isolated peptides are tested by, for example, T cell biology techniques, to determine whether the peptides elicit a T cell response or induce T cell non-responsiveness. Those peptides found to elicit a T cell response or induce T cell non-responsiveness are defined as having T cell stimulating activity.

Screening peptides of the invention for human T cell stimulating acitivity can be accomplished using one or more of several different assays. For example, *in vitro*, T cell stimulatory activity is assayed by contacting a peptide of the invention with an antigen presenting cell which presents appropriate MHC molecules in a T cell culture. Presentation of a peptide of the invention in association with appropriate MHC molecules to T cells, in conjunction with the necessary costimulation has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and interleukin-4. The culture supernatant can be obtained and assayed for interleukin-2 or other known cytokines. For example, any one of several conventional assays for interleukin-2 can be employed, such as the assay described in *Proc. Natl. Acad. Sci USA*, 86:1333 (1989) the pertinent portions of which are

incorporated herein by reference. A kit for an assay for the production of interferon is also available from Genzyme Corporation (Cambridge, MA).

A common assay for T cell proliferation entails measuring tritiated thymidine incorporation. The proliferation of T cells can be measured in vitro by determining the amount of ^{3}H-labeled thymidine incorporated into the replicating DNA of cultured cells. Therefore, the rate of DNA synthesis and, in turn, the rate of cell division can be quantified.

A peptide may also be screened for the ability to reduce T cell responsiveness. The ability of a peptide known to stimulate T cells, to inhibit or completely block the activity of a purified native *Lol p* V protein allergen or portion thereof and induce a state of T cell nonresponsiveness or reduced T cell responsiveness, can be determined using subsequent attempts at stimulation of the T cells with antigen presenting cells that present a native *Lol p* V allergen following exposure to a peptide of the invention. If the T cells are unresponsive to the subsequent activation attempts, as determined by interleukin-2 synthesis and T cell proliferation, a state of nonresponsiveness has been induced. See, e.g., Gimmi, et al. (1993) *Proc. Natl. Acad.* Sci USA, 90:6586-6590; and Schwartz (1990) *Science,* 248:1349-1356, for assay systems that can be used as the basis for an assay in accordance with the present invention.

Additionally, peptides comprising "cryptic epitopes" may be determined and are also within the scope of this invention. Cryptic epitopes are those determinants in a protein antigen which, due to processing and presentation of the native protein antigen to the appropriate MHC molecule, are not normally revealed to the immune system. However, a peptide comprising a cryptic epitope is capable of causing T cells to become non-responsive, and when a subject is primed with the peptide, T cells obtained from the subject will proliferate *in vitro* in response to the peptide or the protein antigen from which the peptide is derived. Peptides which comprise at least one cryptic epitope derived from a protein antigen are referred to herein as "cryptic peptides". To confirm the presence of cryptic epitopes in the above-described T cell proliferation assay, antigen-primed T cells are cultured *in vitro* in the presence of each peptide separately to establish peptide-reactive T cell lines. A peptide is considered to comprise at least one cryptic epitope if a T cell line can be established with a given peptide and T cells are capable of proliferation upon challenge with the peptide and the protein antigen from which the peptide is derived.

It is also possible to modify the structure of a peptide of the invention for such purposes as increasing solubility, enhancing therapeutic or preventive efficacy, or stability

(e.g., shelf life *ex vivo*, and resistance to proteolytic degradation *in vivo*). A modified peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition, to modify immunogenicity and/or reduce allergenicity, or to which a component has been added for the same purpose.

For example, a peptide can be modified so that it maintains the ability to induce T cell anergy and bind MHC proteins without the ability to induce a strong proliferative response or possibly, any proliferative response when administered in immunogenic form. In this instance, critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue and determination of the presence or absence of T cell reactivity). Those residues shown to be essential to interact with the T cell receptor can be modified by replacing the essential amino acid with another, preferably similar amino acid residue (a conservative substitution) whose presence is shown to enhance, diminish but not eliminate, or not affect T cell reactivity. In addition, those amino acid residues which are not essential for T cell receptor interaction can be modified by being replaced by another amino acid whose incorporation may enhance, diminish or not affect T cell reactivity but does not eliminate binding to relevant MHC.

Additionally, peptides of the invention can be modified by replacing an amino acid shown to be essential to interact with the MHC protein complex with another, preferably similar amino acid residue (conservative substitution) whose presence is shown to enhance, diminish but not eliminate, or not affect T cell activity. In addition, amino acid residues which are not essential for interaction with the MHC protein complex but which still bind the MHC protein complex can be modified by being replaced by another amino acid whose incorporation may enhance, not affect, or diminish but not eliminate T cell reactivity. Preferred amino acid substitutions for non-essential amino acids include, but are not limited to substitutions with alanine, glutamic acid, or a methyl amino acid.

In order to enhance stability and/or reactivity, peptides of the invention can also be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein allergen resulting from natural allelic variation. Additionally, D-amino acids, non-natural amino acids or non-amino acid analogues can be substituted or added to produce a modified peptide within the scope of this invention. Furthermore, peptides of the present invention can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers (Wie et al. *supra*) to produce a protein or peptide conjugated with PEG. In addition, PEG can be added during chemical synthesis of a protein or peptide of the invention. Modifications of peptides or portions thereof can also include reduction/ alkylation (Tarr in: *Methods of Protein Microcharacterization*, J.E. Silver ed. Humana

Press, Clifton, NJ, pp 155-194 (1986)); acylation (Tarr, *supra*); chemical coupling to an appropriate carrier (Mishell and Shiigi, eds., *Selected Methods in Cellular Immunology*, WH Freeman, San Francisco, CA (1980); U.S. Patent 4,939,239; or mild formalin treatment (Marsh, *International Archives of Allergy and Applied Immunology*, 41:199-215 (1971)).

To facilitate purification and potentially increase solubility of peptides of the invention, it is possible to add reporter group(s) to the peptide backbone. For example, poly-histidine can be added to a peptide to purify the peptide on immobilized metal ion affinity chromatography (Hochuli, E. et al., *Bio/Technology*, 6:1321-1325 (1988)). In addition, specific endoprotease cleavage sites can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences. In order to successfully desensitize an individual to a protein antigen, it may be necessary to increase the solubility of a peptide by adding functional groups to the peptide or by not including hydrophobic T cell epitopes or regions containing hydrophobic epitopes in the peptides or hydrophobic regions of the protein or peptide. Functional groups such as charged amino acid pairs (e.g., KK or RR) are particularly useful for increasing the solubility of a peptide when added to the amino or carboxy terminus of the peptide.

To potentially aid proper antigen processing of T cell epitopes within a peptide, canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a peptide during recombinant construction of the peptide. The resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell epitopes. In addition, as discussed above, such charged amino acid residues can be added to the amino or carboxy terminus of the peptide and can result in an increase in solubility of a peptide.

Site-directed mutagenesis of DNA encoding a peptide of the invention can be used to modify the structure of the peptide by methods known in the art. Such methods may, among others, include PCR with oligonucleotides containing the sequences encoding the desired amino acids (Ho et al., *Gene*, 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z. et al., *Biochem. Biophys, Res. Comm.*, 161:1056-1063 (1989)). To enhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to change the eukaryotic codons in DNA constructs encoding protein or

peptides of the invention to ones preferentially used in *E. coli*, yeast, mammalian cells, or other eukaryotic cells.

Peptides or antibodies of the present invention can also be used for detecting and diagnosing ryegrass pollinosis. For example, this could be done *in vitro* by combining blood or blood products obtained from an individual to be assessed for sensitivity to ryegrass pollen or another cross reactive pollen such as *Dac g* V, with isolated peptides of *Lol p* V, under conditions appropriate for binding of components in the blood (e.g., antibodies, Tcells, B cells) with the peptide(s) and determining the extent to which such binding occurs. Other diagnostic methods for allergic diseases in which the protein, peptides or antibodies of the present invention will be useful include radio-allergergosorbent test (RAST), paper radioimmunosorbent test (PRIST), enzyme linked immunosorbent assay (ELISA), radioimmunoassays (RIA), immuno-radiometric assays (IRMA), luminescence immunoassays (LIA), histamine release assays and IgE immunoblots.

The presence in individuals of IgE specific for at least one protein allergen and the ability of T cells of the individuals to respond to T cell epitope(s) of the protein allergen can be determined by administering to the individuals an Immediate Type Hypersensitivity test and a Delayed Type Hypersensitiity test. The individuals are administered an Immediate Type Hypersensitivity test (see e.g., *Immunology* (1985) Roitt, I.M., Brostoff, J., Male, D.K. (eds), C.V. Mosby Co., Gower Medical Publishing, London, NY, pp. 19.2-19.18; pp. 22.1-22.10) utilizing the protein allergen or a portion thereof, or a modified form of the protein allergen or a portion thereof, each of which binds IgE specific for the allergen. The same individuals are administered a Delayed Type Hypersensitivity test prior to, simultaneously with, or subsequent to administration of the Immediate Type Hypersensitivity test. Of course, if the Immediate Type Hypersensitivity test is administered prior to the Delayed Type Hypersensitivity test, the Delayed Type Hypersensitivity test would be given to those individuals exhibiting a specific Immediate Type Hypersensitivity reaction. The Delayed Type Hypersensitivity test utilizes a modified form of the protein allergen or a portion thereof, the protein allergen produced recombinantly, or a peptide derived from the protein allergen, each of which has human T cell stimulating activity and each of which does not bind IgE specific for the allergen in a substantial percentage of the population of individuals sensitive to the allergen (e.g., at least about 75%). Those individuals found to have both a specific Immediate Type Hypersensitivity reaction and a specific Delayed Type Hypersensitivity reaction may be treated with a therapeutic composition comprising the same modified form of the protein

or portion thereof, the recombinantly produced protein allergen, or the peptide, each as used in the Delayed Type Hypersensitivity test.

Isolated peptides of the invention when administered in a therapeutic regimen to a *Lol p* V-sensitive individual, or an individual allergic to an allergen cross-reactive with *Lol p* V such as *Dac g* V, are capable of modifying the allergic response of the individual to *Lol p* V ryegrass pollen allergen or such cross-reactive allergen, and preferably are capable of modifying the B-cell response, T-cell response or both the B-cell and the T-cell response of the individual to the allergen. As used herein, modification of the allergic response of an individual sensitive to a ryegrass pollen allergen or cross-reactive allergen can be defined as non-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See e.g. Varney et al, *British Medical Journal*, 302:265-269 (1990)) including diminution in ryegrass pollen induced asthmatic symptoms. As referred to herein, a diminution in symptoms includes any reduction in the allergic response of an individual to the allergen after the individual has completed a treatment regimen with a peptide or protein of the invention. This diminution may be subjective (i.e. the patient feels more comfortable in the presence of the allergen). Diminution in symptoms can be determined clinically as well, using standard skin tests as is known in the art.

Lol p V peptides of the present invention which have T cell stimulating activity, and thus comprise at least one T cell epitope are particularly desirable for therapeutic purposes. In referring to an epitope, the epitope will be the basic element or smallest unit of recognition by a receptor, particularly immunoglobulins, histocompatibility antigens and T cell receptors where the epitope comprises amino acids essential to receptor recognition. Amino acid sequences which mimic those of the epitopes and which are capable of down regulating or reducing allergic response to *Lol p* V can also be used. T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to a protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms and its production is influenced early in the cascade of events, at the level of the T helper cell, by the nature of the lymphokines secreted.

Exposure of ryegrass pollen patients to isolated *Lol p* V peptides of the present invention which comprise at least one T cell epitope and are derived from *Lol p* V protein allergen may cause appropriate T cell subpopulations to become nonresponsive or have a reduced response to the protein allergen and thus do not participate in stimulating an immune response upon such exposure. In addition, administration of a peptide of the invention or portion thereof which comprises at least one T cell epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring *Lol p* V protein allergen or portion thereof (e.g. result in a decrease of IL-4 and/or an increase in IL-2). Furthermore, administration of such peptide of the invention may influence T cell subpopulations which normally participate in the response to the naturally occurring allergen such that these T cells are drawn away from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and lung) towards the site(s) of therapeutic administration of the fragment or protein allergen. This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate the usual immune response at the site of normal exposure to the allergen, resulting in a diminution in allergic symptoms.

The isolated *Lol p* V peptides of the invention can be used in methods of diagnosing, treating and preventing allergic reactions to *Lol p* V allergen or a cross reactive protein allergen. Thus the present invention provides compositions useful in allergy diagnosis and/or useful in allergy therapy comprising isolated *Lol p* V peptides or portions thereof. Such compositions will typically also comprise a pharmaceutically acceptable carrier or diluent when intended for *in vivo* administration. Therapeutic compositions of the invention may also comprise synthetically prepared *Lol p* V peptides and a pharmaceutically acceptable carrier or diluent.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. *Lol p* V peptides or portions thereof may be administered to an individual in combination with, for example, an appropriate diluent, a carrier and/or an adjuvant. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutically acceptable carriers include polyethylene glycol (Wie et al. (1981) *Int. Arch. Allergy Appl. Immunol.* 64:84-99) and liposomes (Strejan et al. (1984) *J. Neuroimmunol*, 7: 27).

The therapeutic compositions of the invention are administered to ryegrass allergen sensitive individuals or individuals sensitive to an allergen which is immunologically cross-reactive with house ryegrass allergen (i.e. *Dactylis glomerata*, or *Sorghum halepensis*, etc.). For the purposes of inducing T cell non responsiveness, therapeutic

compositions of the invention are preferably administered in non-immunogenic form, e.g. which does not contain adjuvant. While not intending to be limited to any theory, it is believed that T cell non responsiveness or reduced T cell responsiveness is induced as a result of not providing an appropriate costimulatory signal sometimes referred to as a "second signal" Briefly, it is believed that stimulation of T cells requires two types of signals, the first is the recognition by the T cell via the T cell receptor of appropriate MHC-associated processed antigens on antigen presenting cells (APCs) and the second type of signal is referred to as a costimulatory signal(s) or "second signal" which may be provided by certain competent APCs. When a composition of the invention is administered without adjuvant, it is believed that competent APCs which are capable of producing the second signal or costimulatory signal are not engaged in the stimulation of appropriate T cells therefore resulting in T cell nonresponsiveness or reduced T cell responsiveness. In addition, there are a number of antibodies or other reagents capable of blocking the delivery of costimulatory signals such as the "second signal" which include, but are not limited to B7 (including B7-1, B7-2, and BB-1), CD28, CTLA4, CD40 CD40L CD54 and CD11a/18 (Jenkins and Johnson, *Current Opinion in Immunology*, 5:361-367 (1993), and Clark and Ledbetter, *Nature*, 367:425-428 (1994)) Thus, a peptide of the invention may be administered in nonimmunogenic form as discussed above, in conjunction with a reagent capable of blocking costimulatory signals such that the level of T cell nonresponsiveness is enhanced.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known procedures at dosages and for periods of time effective to reduce sensitivity (i.e., reduce the allergic response) of the individual to the allergen. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to ryegrass pollen, the age, sex, and weight of the individual, and the ability of the protein or fragment thereof to elicit an antigenic response in the individual.

The active compound (i.e., protein or fragment thereof) may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated within a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

For example, preferably about 1 µg- 3 mg and more preferably from about 20-750 µg of active compound (i.e., protein or fragment thereof) per dosage unit may be

administered by injection. Dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

To administer a peptide by other than parenteral administration, it may be necessary to coat the protein with, or co-administer the protein with, a material to prevent its inactivation. For example, peptide or portion thereof may be co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J. Neuroimmunol.*, 7:27).

The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethyline glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions of dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glyceral, propylene glycol, and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thirmerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol and sorbitol or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about, including in the composition, an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating active compound (i.e., protein or peptide) in the required amount in an appropriate solvent with one or a

combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile indectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (i.e., protein or peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When a peptide of the invention is suitably protected, as described above, the peptide may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The peptide and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit contains between from about 10 μg to about 200 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservative, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially

non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit from as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

Various isolated peptides of the invention derived from ryegrass pollen protein *Lol p* V are shown in Fig. 2 (SEQ ID NO:3-29). Peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p* V are also within the scope of the invention. As used herein a region may include the amino acid sequence of a peptide of the invention as shown in Fig. 2 or the amino acid sequence of a portion of such peptide.

As discussed in Example 2, human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to *Lol p* V allergen, (i.e., an individual who has an IgE mediated immune response to *Lol p* V allergen) with a peptide derived from the allergen and determining whether proliferation of T cells occurs in response to the peptide as measured, e.g., by cellular uptake of tritiated thymidine. Stimulation indices for responses by T cells to peptides can be calculated as the maximum CPM in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background level is considered "positive". Positive results are used to calculate the mean stimulation index for each peptide for the group of patients tested. In Figs. 4 and 5 the mean T cell stimulation index is indicated above the

bar. Preferred peptides of this invention comprise at least one T cell epitope and have a mean T cell stimulation index of greater than or equal to 2.0. A peptide having a mean T cell stimulation index of greater than or equal to 2.0 in a significant number of ryegrass pollen sensitive patients tested is considered useful as a therapeutic agent. Preferred peptides have a mean T cell stimulation index of at least 2.5, more preferably at least 3.0, more preferably at least 3.5, more preferably at least 4.0, more preferably at least 5.0 and most preferably at least about 6. For example, peptides of the invention having a mean T cell stimulation index of at least 5, as indicated by data shown in Figs 4 and 5, include peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-8 (SEQ ID NO:10), LPIX-17 (SEQ ID NO:19) and LPIX-19 (SEQ ID NO:21).

In addition, preferred peptides have a positivity index (P.I.) of at least about 60, more preferably about 100, more preferably at least about 200 and most preferably at least about 300. The positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to ryegrass pollen (e.g., preferably a population of at least 15 individuals, more preferably a population of at least 30 individuals or more), who have a T cell stimulation index to such peptide of at least 2.0. Thus, the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell response to a peptide in a population of individuals sensitive to ryegrass pollen. In Fig. 4, the bar represents the positivity index and the percent of individuals tested who have a T cell stimulation index of at least 2.0 to that peptide are indicated in parenthesis above each bar (the mean T cell stimulation index is also indicated above each bar). For example, as shown in Fig. 4, *Lol p* V peptide LPIX-5 (SEQ ID NO:7) has a mean S.I. of 5.8 and 26.3% of positive responses in the group of individuals tested resulting in a positivity index of 152.54. *Lol p* V peptides having a positivity index of at least about 100 and a mean T cell stimulation index of at least about 4 include: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), and LPIX-17 (SEQ ID NO:19).

In Fig. 5, the bar represents the cumulative rank of the peptide response in the group of patients tested as described in Example 2. To determine the cumulative rank, the 5 peptides with the highest S.I. in each individual were determined and assigned a numerical rank in descending order, with 5 representing the strongest response. The ranks for each peptide were then summed for the entire group of patients tested to determine the cumulative rank for the peptide. Above each bar is the mean S.I. for each peptide and the percent of positive responses (in parenthesis) with an S.I. of at least 2 to the peptide in the group of patients tested.

In order to determine precise T cell epitopes by, for example, fine mapping techniques, a peptide having T cell stimulating activity and thus comprising at least one T cell epitope as determined by T cell biology techniques is modified by addition or deletion of amino acid residues at either the amino or carboxy terminus of the peptide and tested to determine a change in T cell reactivity to the modified peptide. Following this technique, peptides are selected and produced recombinantly or synthetically. Peptides are selected based on various factors, including the strength of the T cell response to the peptide (e.g., stimulation index), the frequency of the T cell response to the peptide in a population of individuals sensitive to ryegrass pollen, and the potential cross-reactivity of the peptide with other allergens from other species of grasses as discussed earlier i.e. *Dactylis glomerata*. The physical and chemical properties of these selected peptides (e.g., solubility, stability) are examined to determine whether the peptides are suitable for use in therapeutic compositions or whether the peptides require modification as described herein. The ability of the selected peptides or selected modified peptides to stimulate human T cells (e.g., induce proliferation, lymphokine secretion) or cause appropriate T cell populations to become non-responsive or have a reduced response to the protein allergen is determined.

In addition, it may be desirable to further modify peptides such as LPIX-4 (SEQ ID NO:6),-5 (SEQ ID NO:7),-6 (SEQ ID NO:8),-11 (SEQ ID NO:13),-12 (SEQ ID NO:14),-16 (SEQ ID NO:18),-17 (SEQ ID NO:19)and -20 (SEQ ID NO:22) for purposes of increasing solubility or stability. Modifications to improve solubility include truncation from either the amino or carboxyl terminus of the peptide or both termini to remove hydrophilic amino acids such as Val, Ile, Leu, Phe, Tyr and Trp. Residues removed by truncation may also be replaced with charged hydrophilic amino acids such as Asp, Glu, Lys and Arg or neutral hydrophilic amino acids such as Ser, Pro, Gly or Ala. Such amino acids may be of either the R or S optical configuration.

Other modifications to improve solubility include attachment of hydrophilic polymers to either the amino- or carboxy terminus of the peptides or to both. Such polymers may be polyanionic, polycationic or neutral (such as polyoxyethylene).

Modifications to improve stability include deletion or replacement of Asn and Gln residues and elimination ot Asn-Gly, Asp-Gly and Asp-Pro sequences.

Specific examples of modifications listed above would be removal of the N-terminal Val and C-terminal Val-His-Ala-Val from peptide LIX-12. The resulting

truncated peptide could be used directly or the deleted residues could be replaced by combinations of the polar amino acids Asp, Glu, Lys and Arg. Similarly, the N-terminal sequence Gly-Phe and C-terminal sequence Phe-Lys-Ile could be removed from peptide LPIX-5 (SEQ ID NO:7).

Additionally, preferred T cell epitope-containing peptides of the invention do not bind immunoglobulin E (IgE) or bind IgE to a substantially lesser extent (e.g. at least 100 fold less and more preferably at least 1000 fold less) than the protein allergen from which the peptide is derived. The major complications of standard immunotherapy are IgE-mediated responses such as anaphylaxis. Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the release of mediators (e.g., histamine, serotonin, eosinophil chemotacic factors). Thus, anaphylaxis in a substantial percentage of a population of individuals sensitive to *Lol p* V could be avoided by the use in immunotherapy of a peptide or peptides which do not bind IgE in a substantial percentage (e.g., at least about 75%) of a population of individuals sensitive to *Lol p* V allergen, or if the peptide binds IgE, such binding does not result in the release of mediators from mast cells or basophils. The risk of anaphylaxis could be reduced by the use in immunotherapy of a peptide or peptides which have reduced IgE binding. Moreover, peptides which have minimal IgE stimulating activity are desirable for therapeutic effectiveness. Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production and/or IL-4 production stimulated by the native *Lol p* V protein allergen. Similarly, IL-4 production can be compared, with reduced IL-4 production indicating lessened IgE stimulating activity.

If a peptide of the invention is to be used as a diagnostic reagent, it is not necessary that the peptide or protein have reduced IgE binding activity compared to the native *Lol p* V allergen. IgE binding activity of peptides can be determined by, for example, using various types of enzyme linked immunosorbent assays (ELISA).

Preferred T cell epitope containing peptide of the invention, when administered to a ryegrass pollen-sensitive individual or an individual sensitive to an allergen which is immunologically related to ryegrass pollen allergen such as *Dac g* I, in a therapeutic treatment regimen, is capable of modifying the allergic response of the individual to the allergen. Particularly, such preferred *Lol p* V peptides of the invention comprising at least one T cell epitope of *Lol p* V or at least two regions derived from *Lol p* V, each comprising at least one T cell epitope, when administered to an individual sensitive to

ryegrass pollen are capable of modifying T cell response of the individual to the allergen and are useful as therapeutics in addressing sensitivity to grasses.

A preferred isolated *Lol p* V peptide of the invention comprises at least one T cell epitope of the *Lol p* V and accordingly the peptide comprises at least approximately seven amino acid residues. For purposes of therapeutic effectiveness, preferred therapeutic compositions of the invention preferably comprise at least two T cell epitopes of *Lol p* V, and accordingly, a preferred peptide comprises at least approximately eight amino acid residues and preferably at least fifteen amino acid residues. Additionally, therapeutic compositions comprising preferred isolated peptides of the invention preferably comprise a sufficient percentage of the T cell epitopes of the entire protein allergen (i.e. at least about 40% and more preferably about 60% of the T cell reactivity to the entire protein allergen) such that a therapeutic regimen of administration of the composition to an individual sensitive to ryegrass pollen, results in T cells of the individual being tolerized to the protein allergen. Synthetically produced peptides of the invention comprising up to approximately forty-five amino acid residues in length, and most preferably up to approximately thirty amino acid residues in length are particularly desirable as increases in length may result in difficulty in peptide synthesis. Peptides of the invention may also be produced recombinantly as described earlier, and it is preferable that peptides of 45 amino acids or longer be produced recombinantly.

Peptides derived from the *Lol p* V protein allergen which can be used for therapeutic purposes comprise at least one T cell epitope of *Lol p* V and comprise all or a portion of the following peptides: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (the sequences of which are shown in Fig. 2) wherein the portion of the peptide preferably has a mean T cell stimulation index (S.I.) equivalent to, or greater than the mean T cell stimulation index of the peptide from which it is derived (e.g. as shown in Fig. 5, the S.I. for LPIX-16 (SEQ ID NO:18) is shown above the bar to be 3.7, therefore any portion of LPIX-16 preferably has a mean S.I. of 3.7). Even more preferably peptides

derived from the *Lol p* V protein allergen which can be used for therapeutic purposes comprise all or a portion of the following peptides: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28) as shown in Fig. 2. Even more preferably, peptides derived from Lol p V protein allergen which can be used for therapeutic purposes comprise all or a portion of the following peptides: LPIX-1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12). LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

One embodiment of the present invention features a peptide or portion thereof of *Lol p* V which comprises at least one T cell epitope of the protein allergen and has a formula X_n-Y-Z_m. According to the formula, Y is an amino acid sequence selected from the group consisting of: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (the sequences of which are shown in Fig. 2). In addition, X_n are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of the protein allergen and Z_m are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of the protein allergen. In the formula, n is 0-30 and m is 0-30. Preferably, the peptide or portion thereof has a mean T cell stimulation index equivalent to greater than the mean T cell stimulation index of Y as shown in Fig. 4. Preferably, amino acids comprising the amino terminus of X and the carboxy terminus of Z are selected from

charged amino acids, i.e., arginine (R), lysine (K), histidine (H), glutamic acid (E) or aspartic acid (D); amino acids with reactive side chains, e.g., cysteine (C), asparagine (N) or glutamine (Q); or amino acids with sterically small side chains, e.g., alanine (A) or glycine (G). Preferably n and m are 0-5; most preferably n + m is less than 10.

Another embodiment of the present invention provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p* V and accordingly each region comprises at least approximately seven amino acid residues. These peptides comprising at least two regions can comprise up to 100 or more amino acid residues but preferably comprise at least about 14, even more preferably at least about 20, and most preferably at least about 30 amino acid residues of the *Lol p* V allergen. If desired, the amino acid sequences of the regions can be produced and joined by a linker to increase sensitivity to processing by antigen-presenting cells. Such linker can be any non-epitope amino acid sequence or other appropriate linking or joining agent. To obtain preferred peptides comprising at least two regions, each comprising at least one T cell epitope, the regions are arranged in the same or a different configuration from a naturally-occurring configuration of the regions in the allergen. For example, the regions containing T cell epitope(s) can be arranged in a noncontiguous configuration and can preferably be derived from the same protein allergen. Noncontiguous is defined as an arrangement of regions containing T cell epitope(s) which is different than that of the native amino acid sequence of the protein allergen from which the regions are derived. Furthermore, the noncontiguous regions containing T cell epitopes can be arranged in a nonsequential order (e.g., in an order different from the order of the amino acids of the native protein allergen from which the region containing T cell epitope(s) are derived in which amino acids are arranged from an amino terminus to a carboxy terminus). A peptide of the invention can comprise at least 15%, at least 30%, at least 50% or up to 100% of the T cell epitopes of *Lol p* V but does not comprise the entire amino acid sequence of *Lol p* V.

The individual peptide regions can be produced and tested to determine which regions bind immunoglobulin E specific for *Lol p V* and which of such regions would cause the release of mediators (e.g., histamine) from mast cells or basophils. Those peptide regions found to bind immunoglobulin E and to cause the release of mediators from mast cells or basophils in greater than approximately 10-15% of the allergic sera tested are preferably not included in the peptide regions arranged to form preferred peptides of the invention.

Examples of preferred peptide regions which do not appear to bind to IgE in preliminary IgE binding data studies (Example 3) include the amino acid sequences of

such regions being shown in Fig. 2 (SEQ ID NO:3-29), or portions of said regions comprising at least one T cell epitope.

Preferred peptides comprise various combinations of two or more of the above-discussed preferred regions, or a portion thereof. Preferred peptides comprising a combination of two or more regions (each region having an amino acid sequence as shown in Fig. 2), include the following:

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25) and LPIX-26 (SEQ ID NO:28);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22)
LPIX-5 (SEQ ID NO:7), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), and LPIX-20 (SEQ ID NO:22);
LPIX-6 (SEQ ID NO:8), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-12 (SEQ ID NO:14), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22); and
LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22).

In yet another aspect of the present invention, a composition is provided comprising at least two peptides (e.g., a physical mixture of at least two peptides), each comprising at least one T cell epitope of *Lol p* V. Such compositions can be in the form of a composition additionally with a pharmaceutically acceptable carrier of diluent for therapeutic uses, or with conventional non-pharmaceutical excipients for reagent use. When used therapeutically, an effective amount of one or more of such compositions can be administered simultaneously or sequentially to an individual sensitive to ryegrass pollen.

In another aspect of the invention, combinations of *Lol p* V peptides are provided which can be administered simultaneously or sequentially. Such combinations may comprise therapeutic compositions comprising only one peptide, or more peptides if desired. Such compositions may be used simultaneously or sequentially in preferred combinations.

Preferred compositions and preferred combinations of *Lol p* V peptides which can be administered or otherwise used simultaneously or sequentially (comprising peptides having amino acid sequences shown in Fig. 2) include the following combinations:

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19) and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25) and LPIX-26 (SEQ ID NO:28);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);

LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);

LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), and LPIX-20 (SEQ ID NO:22);
LPIX-6 (SEQ ID NO:8), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-12 (SEQ ID NO:14), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22); and
LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22).

In another aspect of the present invention, a therapeutic composition is provided comprising at least two peptides (e.g. a physical mixture of at least two peptides, each peptide comprising at least one epitope) wherein at least one peptide, comprises an amino acid sequence or portion thereof derived from *Lol p* V selected from the following group: LPIX-1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (as shown in Fig. 2), and wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p* I selected from the following group: LPI-1 (SEQ ID NO:30), LPI-1.1 (SEQ ID NO:31), LPI-2 (SEQ ID NO:32), LPI-3 (SEQ ID NO:55), LPI-4 (SEQ ID NO:33), LPI-4.1 (SEQ ID NO:34), LPI-5 (SEQ ID NO:35), LPI-6 (SEQ ID NO:36), LPI-7 (SEQ ID NO:37), LPI-8 (SEQ ID NO:38), LPI-9 (SEQ ID NO:39), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-12 (SEQ ID NO:42), LPI-13 (SEQ ID NO:43), LPI-14 (SEQ ID NO:44), LPI-15 (SEQ ID NO:45), LPI-16 (SEQ ID NO:46), LPI-16.1 (SEQ ID NO:47), LPI-17 (SEQ ID NO:48), LPI-18 (SEQ ID NO:49), LPI-19 (SEQ ID NO:50), LPI-20 (SEQ ID NO:56), LPI-21 (SEQ ID NO:51), LPI-22 (SEQ ID NO:52), and LPI-23 (SEQ ID NO:53).(as shown in Fig. 3). The isolation and cloning of the clones encoding *Lol p* I as well as the synthesis of the various *Lol p* I

peptides shown in Fig. 3, along with human T cell studies using *Lol p* I and using various peptides derived from *Lol p* I are described in PCT/US94/02537, which is hereby incorporated by reference in its entirety.

Preferably, a therapeutic composition comprises at least four, five, six, seven, or eight peptides wherein at least two, three or four peptides are derived from *Lol p* V and are selected from the following group: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPI-6 (SEQ ID NO:36), LPIX-11 (SEQ ID NO: 13), LPI-12 (SEQ ID NO:42), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22), and at least two, three or four peptides are derived from *Lol p* I and selected from the following group: LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53); for example, a preferred therapeutic composition comprises at least two peptides of *Lol p* I and two peptides of *Lol p* V, or two peptides of *Lol p* I and three peptides of *Lol p* V, or three peptides from *Lol p* I and three peptides from *Lol p* V, or three peptides from *Lol p* I and four peptides from *Lol p* V, or four peptides from *Lol p* I and four peptides from *Lol p* V, or four peptides from *Lol p* I and three peptides from *Lol p* V.

In another aspect of the present invention a method is provided comprising administering a combination of peptides or portions thereof derived from *Lol p* V and *Lol p* I which can be administered simultaneously or sequentially; each of such peptides can be in the form of a therapeutic composition with a pharmaceutically acceptable carrier or diluent. Examples of preferred compositions and preferred combinations comprising *Lol p* V and *Lol p* I peptides or portions thereof, which can be administered simultaneously or sequentially comprise the following combinations:

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20, LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID

NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);-

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22); LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ. ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ. ID NO:10), LPIX-9 (SEQ. ID NO:11), LPIX-11 (SEQ. ID NO:13), LPIX-12 (SEQ. ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ. ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ. ID NO:25), LPIX-26 (SEQ. ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22); and--.

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22).

In addition, a composition is provided comprising at least two *Lol p* I peptides (e.g. a physical mixture of at least two peptides), each comprising at least one T cell epitope of *Lol p* I. Such compositions can be administered in the form of a therapeutic composition with with a pharmaceutically acceptable carrier or diluent to treat ryegrass sensitivity and particularly, sensitivity to *Lol p* I protein allergen. Preferred compositions and preferred combinations of *Lol p* I peptides which can be administered simultaneously or sequentially (comprising peptides having the amino acid sequences shown in Fig. 3 include the following combinations:

LPI-16 (SEQ ID NO:46), and LPI-20 (SEQ ID NO:56);
LPI-18 (SEQ ID NO:49), and LPI-20 (SEQ ID NO:56);
LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);
LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), and LPI-20 (SEQ ID NO:56);
LPI-16 (SEQ ID NO:46), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);
LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53);
LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), and LPI-23 (SEQ ID NO:53).

Any of the compositions described herein are useful in the manufacture of a medicament for treating sensitivity to ryegrass pollen allergen or an immunologically cross reactive allergen in an individual.

The present invention if further illustrated by the following non-limiting Figures and Examples.

EXAMPLE I

Purification of Native *Lol p* V from ryegrass pollen

A. Production and purification of monoclonal antibody (mAb) 1B9.

Balb/c mice were immunized with crude *Dactylis glomerata* (orchard grass/cocksfoot grass) pollen extract and antibody secreting clones were generated as described (Walsh *et al.*, *Int.. Arch. Allergy Appl. Immunol.*, 1990, 91: 419-425). MAb 1B9 hybridoma clone which cross-reacts to *Lol p* V was obtained from Dr. Walker (Univ. Birmingham, Wolfson Research Lab, Birmingham,UK). Ascitic fluid generated from Balb/c mice was produced by contract (Babco, Richmond, CA). The antibodies were purified from ascites fluid by $(NH_4)_2SO_4$ precipitation (50% saturation). The pellet was resuspended in 10mM phosphate buffer, pH 7.5 and dialyzed against the same buffer at 4°C overnight and then fractionated by ion-exchange chromatography

on FPLC Q-Sepharose (Pharmacia, Piscataway, NJ) using linear gradient 0-0.5 M NaCl. IgG was eluted between 0.15-0.2 M NaCl concentration.

B. Preparation of 1B9 immunoaffinity column

Purified 1B9 was coupled to Affigel-10 (Biorad, Richmond, CA) using 3-4 mg protein/mL of gel according to manufacturer's instructions. In brief, PFLC Q-Sepharose purified mAb 1B9 was dialyzed against 0.1M MOPS buffer, pH 7.5 with two to three changes overnight at 4°C. The Affigel-10 resin was washed with deionized cold H_2O in a scintered glass funnel. The washed resin was mixed with the 1B9 antibody for four hours at 4°C, followed by an one-hour blocking step with 1 M ethanolamine, pH 8.0. Resin was packed into a column, washed with PBS and then stored in PBS + 0.05% sodium azide.

C. Affinity purification of *Lol p* V from ryegrass pollen

100g defatted ryegrass pollen (purchased from Greer Laboratories, Lenoir, NC) was extracted in 1 liter extraction buffer containing 0.05 M phosphate buffer, pH 7.2, 0.15 M NaCl, phenyl methyl sulfonyl fluoride (170 µg/mL), leupeptin (1 µg/mL), pepstatin (1µg/mL) and soybean trypsin inhibitor (1µg/mL).

The pollen was extracted by stirring the solution overnight at 4°C, followed by centrifugation at 12,000 x g for 100 minutes. The insoluble materials were re-extracted in 0.5-1.0L extraction buffer and then the supernatants were combined and depigmented by batch absorption onto 100 mL DE-52 cellulose (Whatman, Maidstone, England) equilibrated with 0.05 M phosphate buffer + 0.3 M NaCl, pH 7.2.

The unbound materials were loaded onto the 1B9-Affigel-10 column at a flow rate of 0.5ml/min. The column was then washed extensively with PBS, PBS + 0.5 M NaCl and once again with PBS before elution of the *Lol p* V allergens with 0.1 M glycine, pH 2.7. Fractions were neutralized with 1 M Tris, pH 11.0 immediately. These affinity-purified materials were used in IgE studies and T cell epitope mapping.

Physicochemical properties of affinity-purified *Lol p* V

The 1B9 affinity-purified material was analyzed by SDS-PAGE. As shown in Fig. 15, *Lol p* V exists as multiple bands with molecular weight ranged from 29,000 - 22,000. All these components were reactive with 1B9 by Western blotting analysis (data not shown). These components were electroblotted onto ProBlott membrane (Applied Biosystems, Foster City, CA),

stained by Coomassie blue and the three major bands were excised and sequenced on a Beckman LF-3000 sequencer (Beckman Instruments, Carlsbad, CA). N-terminal amino acid sequence of the three bands are shown in Table I. The sequencing data shows that the middle and lower molecular weight bands represent N-terminal cleavage products of the higher molecular weight component. The N-terminus sequence was identical to the cloned *Lol p* V (12R) (see PCT application publication number WO93/04174). The 5 proline residues at the N-terminus were found to be all hydroxyprolines, which seemed to be common to Group V allergens from Northern grasses (Matthiesen, F. et al., 1991, *Clin. Exp. Allergy*, 21:297-307). We also determined the 1B9-affinity purified material by amino acid analysis (Table 2) and the data were very similar to the *Lol p* V and other group V allergens from Northern grasses reported by Klysner et al., (*Clin. Experimental Allergy*, 1992, 22:491-497). Furthermore, Western blot analysis using specific anti-group I mAb (data not shown) demonstrated Group I proteins could not be detected in these preparations. Thus, taken together these data suggest that the 1B9-affinity purified preparations contained only Group V allergens.

Table 1

N-terminal amino acid sequence and cleavage site of *Lol p* V allergen

amino acid #	1	↓ 11	↓
Lol p V	A D A G Y T P'	A A A A T P'	A T P' A A T P'

	21	31
	A A A G G K A T	T D E Q K

P' represents hydroxyproline

The N-terminal sequence was determined from the three major bands electroblotted onto ProBlott membrane. The upper band starts with amino acid 1 whereas the middle and the lower bands start at amino acid 9 and 18, respectively. The arrows indicate the cleavage sites.

Table 2 : Amino acid composition of Group V allergens

Amino acid	Mole %				
	Phl p V [a]	*Lol p* V [a]	*Lol p* V [b] expt 1	expt 2	expt 3
Asx	5.4	6.3	5.3	6.7	7.5
Thr	7.6	8.6	7.4	8.7	9.2
Ser	5.1	2.0	3.3	2.3	2.7
Glx	10.2	9.8	7.4	8.8	8.9
Gly	6.4	4.0	7.2	5.2	4.8
Ala	25.7	29.0	27.7	31.3	31.7
Cys	0.0	1.0	----	----	----
Val	6.6	6.4	5.5	5.5	6.4
Met	0.7	0.3	0.5	0.3	0 8
Ile	3.6	3.4	3.5	2.9	3.1
Leu	4.7	5.9	6.5	5.0	5.3
Tyr	3.5	3.0	2.9	2.5	1.7
Phe	4.1	5.0	4.8	4.0	4.5
His	0.8	0.3	----	0.2	0.5
Lys	8.8	9.8	11.0	9.2	6.0
Arg	1.0	0.4	0.6	0.4	0.8
Pro	4.5	4.9	5.4 [c]	4.7 [c]	3.7 [c]
Hyp	1.4	N.R.	1.5 [c]	1.8 [c]	1.7 [c]

N.R. (Not reported)

a values reported by Klysner, S. *et al.* Clin. Exp. Allergy (1992) 22: 491-497.

b the amino acid composition was determined from mAb 1B9-affinity purified materials and values obtained from three experiments are presented.

c the content of proline and hydroxyproline was determined by peak height since the hydroxyproline peak was very broad due to an contaminant which eluted at the trailing edge of the hydroxyproline peak. All the other amino acids were determined by peak areas.

Example 2 - Human T Cell Studies with *Lol p* V

Synthesis of Overlapping Peptides

The amino acid sequence of *Lol p* V was deduced from the cDNA sequence of clone 12R (SEQ ID NO:2) ATCC number 69475 as shown in Fig. 1. The details of the isolation and cloning of clone 12R encoding *Lol p* V (described as *Lol p* Ib.1) are given in PCT application publication number WO93/04174 incorporated herein by reference in its entirety. One example of expression of recombinantly produced *Lol p* V encoded by clone 12R is given in Example 4, to follow.

Ryegrass *Lol p* V overlapping peptides were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Fig. 2 shows *Lol p* V peptides used in these studies. The peptide names are consistent throughout.

T Cell Responses to Ryegrass Antigen Peptides

Peripheral blood mononuclear cells (PBMC) were purified by lymphocyte separation medium (LSM) centrifugation of 60 ml of heparinized blood from grass-allergic patients who exhibited clinical symptoms of seasonal rhinitis and were skin test positive for grass. Long-term T cell lines were established by stimulation of $2x10^6$ PBL/ml in bulk cultures of complete medium (IRPMI-164), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, $5x10^{-5}$M 2-mercaptoethanol, and 10 mM HEPES, supplemented with 5% heat-inactivated human AB serum, with 10 µg/ml of affinity purified native *Lol p* V for 6 days at 37°C in a humidified 5% CO_2 incubator to select for *Lol p* V reactive T Cells. This amount of priming antigen was determined to be optimal for the activation of T cells from most grass-allergic patients. Viable cells were purified by LSM centrifugation and cultured in complete medium, supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to 3 weeks until the desired cell number were achieved. The cells were allowed to rest for 4-6 days.

The ability of the T cells to proliferate to selected peptides, recombinant *Lol p* I (r*Lol p* I), purified native *Lol p* V, purified r*Lol p* V, or recombinant *Fel d* I (r*Fel d* I) (chain I), or tetanus toxoid (TT) was then assessed. For assay, $2X10^4$ rested cells were restimulated in the presence of $2X10^4$ autologous Epstein-Barr virus (EBV)-transformed B cells (prepared as described below) or $5X10^4$ irradiated PBL with 2-50 mg/ml of r*Lol p* I, purified native *Lol p* V, r*Fel d* I (Chain I), or r*Lol p* I, in a volume of 200 ml complete medium in duplicate wells in 96-well round-bottom plates for three days. Each well then received 1 mCi tritiated thymidine for 16-20 hours. The counts incorporated were

collected onto glass fiber filter mats and processed for liquid scinitillation counting. The varying antigen dose in assays with r*Lol p* V, purified native *Lol p* V, and recombinant *Lol p* I and antigenic peptides synthesized as described above were determined. The titrations were used to optimize the dose of peptides in T cell assays. The maximum response in a titration of each peptide is expressed as the stimulation index (S.I.). The S.I. is the counts per minute (CPM) incorporated by cells in response to peptide, divided by the CPM incorporated by cells in medium only. An S.I. value equal to or greater than 2 times the background level is considered "positive" and indicates that the peptide contains a T cell epitope. The positive results were used in calculating mean stimulation indices for each peptide for the group of patients tested. The results (not shown) demonstrate that one patient responds well to recombinant *Lol p* V and purified native *Lol* p V, as well as to *Lol p* V peptides but not to r*Fel d* I (Chain I) or TT. This indicated that *Lol p* V T cell epitopes are recognized by T cells from this particular allergic patient and that rLol p V contains such T cell epitopes.

The above procedure was followed with a total of 19 patients. Individual patient results were used in calculating the mean S.I. for each peptide if the patient responded to the purified native *Lol p* V protein at an S.I. of 2.0 or greater and the patient responded to at least one peptide derived from purified native *Lol p* I at an S.I. of 2.0 or greater. A summary of positive experiments from 19 patients is shown in Fig. 4. The numbers above each bar report the mean S.I. for that peptide. The numbers enclosed in the parentheses denote percentage of patients responding to that particular peptide. The bar represents the positivity index for each peptide (% of patients responding multiplied by mean S.I.).

Fig. 5 shows the ranked sum for each peptide derived from the same data as described above. The bar represents the cumulative rank of the peptide response in the group of the 19 patients tested. To determine the cumulative rank, the 5 peptides with the highest S.I. in each individual are determined and assigned a numerical rank in descending order, with 5 representing the strongest response. The ranks for each peptide were then summed for the entire group of patients to determine the cumulative rank for the peptide. Above each bar is the mean S.I. and percent of positive responses (in parenthesis) with an S.I. of at least 2 to the peptide in the group of 19 patients tested. Given the percent positive and the mean T cell stimulation index, the positivity index (P.I.) for each peptide can be calculated by multiplying the two numbers. Fig. 5 shows that LPIX-20 has the highest ranked sum of the peptides in this study.

Example 3

Lol p V as a Major Ryegrass Pollen Allergen

A) ELISA Analysis

To examine the importance of *Lol p* V, both direct and competition ELISA assays were performed. In the direct ELISA, 100µl of 10µg/ml of antigen in Phosphate Buffered Saline, pH 7.4 (PBS) was used to coat Immulon II (Dynatech, Chantilly, VA) 96 well plates for 4 hours at room temperature (RT) or overnight (O/N) at 4°C. In between each step the plates were washed 3X with PBS-T. The excess coating antigen(s) was removed and the wells blocked with 300µl/well 0.5% gelatin + 1mg/ml PVP in PBS for 1 hour at RT. Serially diluted patient plasma or the diluent PBS + 0.05% Tween-20 was incubated in at 100µl/well in duplicate wells overnight at 4°C. Unbound antibody was removed, and the wells incubated with 100µl/well of 2nd Ab (1:1000, biotinylated goat anti-human IgE, KPL Inc., Gaithersburg, MD) for 1 hour at RT. This solution was removed and streptavidin-horse radish peroxidase (HRPO) (1:10000) was added at 100µl/well (SBA Inc., Birmingham, AL) and incubated for 1 hr at RT. 3, 3', 5, 5'-tetramethylbenzidine (TMB) Substrate (KPL, Gaithersburg, MD) was freshly mixed and added at 100µl/well and the color allowed to develop for 1-5 minutes. The reaction was stopped by the addition of 100µl/well 1M phosphoric acid. Plates were read on a MR7000 plate reader (Dynatech, Chantilly, VA) with a 450nm filter. The absorbance levels of duplicate wells were averaged. The results were graphed as absorbance vs. dilution. The competition ELISA were carried out using the same protocol with the following changes: a single dilution of patient plasma (or pooled human plasma (PHP)) was used as the source of IgE; serially diluted antigen was mixed with the plasma and allowed to incubate O/N at 4°C. This plasma was then incubated on duplicate wells. The results are plotted as the absorbance vs. the log of the concentration of competing antigen.

For the direct ELISA, wells were coated with either soluble pollen extract (SPE) of ryegrass pollen or r*Lol p* V (purified native *Lol p* V may have a small amount of *Lol p* I; use of recombinant material assures that the IgE binding is only to *Lol p* V) and human IgE antibody binding to these antigens was analyzed. PHP, consisting of an equal volume of plasma from 20 patients with a ryegrass prick test score of 3+ or greater (PHP-A), or PHP consisting of equal aliquots of plasma from 40 grass skin test reactive patients with

high IgE binding as measured by direct ELISA (PHP-B), or plasma from individual patients were compared in this assay. The results of binding reactivity with PHP-A (Fig. 6), PHP-B (Fig. 7), four individual patients on ryegrass pollen SPE (Fig. 8), and purified r*Lol p* V (Fig. 9) to either SPE or r*Lol p* V, indicate that there is high IgE binding to both the pollen extract and the recombinant protein.

In the competition assay, ELISA wells were coated with ryegrass pollen SPE and then allergic patient IgE binding was measured in the presence of competing ryegrass pollen SPE, purified native *Lol p* V, or r*Lol p* V. The source of allergic IgE in this assay was PHP-A (Figure 10) or individual patient plasma (Figure 11). The competition assays confirm that a significant portion of IgE against *Lol p* SPE is specific for *Lol p* V.

B) Histamine Release Analysis

A histamine release assay was performed on one ryegrass allergic individual, using *Lol p* SPE and r*Lol p* V as the added antigens. This assay is a measure of IgE reactivity through human basophil mediator release, and it is based on the detection of an acylated derivative of histamine using a specific monoclonal antibody (Morel, A.M. and Delaage, M.A.; 1988, J. Allergy Clin. Immunol. 82: 646-654). The reagents for this radioimmunoassay are sold as a kit by Amac Inc. (Westbrook, ME). Whole heparinized blood drawn from a grass allergic individual and then 200µl aliquots were mixed with an equal amount of the grass antigens SPE and r*Lol p* V at various concentrations or the diluent, PACM buffer (25mM PIPES, 100mM NaCl, 5mM KCL, 4mM $CaCl_2$, 1mM $MgCl_2$, 0.003% HSA, pH7.3) in 1.5ml polypropylene. The release reactions were carried out at 37°C for 30 minutes. After this incubation, the samples were centrifuged at 1500 RPM for 3 minutes and the supernatants removed. For the total histamine release, 0.1ml of blood was added to 0.9ml of PACM buffer, vortexed, and then boiled for 3 minutes. The samples were spun at 13000 RPM and the supernatant removed for analysis. Duplicate samples were used to measure total release. All of the supernatants are diluted 1:4 in acylation buffer and the remainder of the assay is performed according to the manufacturer's instructions. The results of this assay, shown in Figure 12, demonstrate strong histamine release over a wide concentration range for both the extract and the recombinant protein.

C) Reactivity to *Lol p* V peptides

Direct ELISA was performed to assess the IgE reactivity to *Lol p* V peptides. In this assay ELISA plates were coated with the set of synthetic *Lol p* V peptides (as shown in Fig. 2) and r*Lol p* V protein. Human IgE binding of PHP-B was incubated on the wells and the resulting binding analyzed. As evidenced in Fig. 13a and Fig. 13b there is no significant binding detected to any of the *Lol p* V peptides in this preliminary assay although there is very high IgE binding to *Lol p* V protein.

D) *Lol p* I and *Lol p* V constitute the major allergens of ryegrass pollen

A separate competition ELISA was done to show that *Lol p* I and *Lol p* V together constitute the major IgE binding proteins of ryegrass pollen SPE. In this assay (Fig 14), PHP-B was used to examine the ability of a mixture of native purified *Lol p* I and *Lol p* V or a mixture of r*Lol p* I and r*Lol p* V to compete for IgE binding to ryegrass pollen SPE. The mixture of purified native proteins competes to background level the IgE binding to ryegrass pollen SPE. The mixture of r*Lol p* I and r*Lol p* V is also able to substantially reduce the amount of IgE available to bind to the SPE coating the plate. The majority of human IgE directed against all of the ryegrass pollen proteins was bound up by the mix of just two proteins (*Lol p* I and *Lol p* V) found in the complex mix of ryegrass pollen SPE proteins. This data implies that these two proteins are major allergens of ryegrass pollen.

Example 4

Expression of *Lol p* V

Expression of *Lol p* V was performed as follows. The λgtII clone 12R was digested with EcoRI. The insert encoding *Lol p* V was ligated into pGEX. A pGEX vector containing *Lol p* V (clone 12R) was digested with EcoR1. The *Lol p* V insert (containing the nucleotide sequence shown in Fig. 1) was isolated by electrophoresis of this digest through a 1% SeaPlaque low melt agarose gel. The insert was then ligated into EcoR1 digested expression vector pET-11d (Novagen, Madison, WI; Jameel et al. (1990) *J. Virol.* 64:3963-3966) modified to contain a sequence encoding 6 histidines (His 6) immediately 3' of the ATG initiation codon followed by a unique *Eco*R I endonuclease restriction site. A second *Eco*R I endonuclease restriction site in the vector, along with neighboring *Cla* I and *Hin*d III endonuclease restriction sites, had previously been removed by digestion with *Eco*R I and *Hin*d III, blunting and religation. The histidine

(His6) sequence was added for affinity purification of the recombinant protein (r*Lol p* V) on a Ni^{2+} chelating column (Hochuli et al. (1987) *J. Chromatog.* 411:177-184; Hochuli et al. (1988) *Bio/Tech.* 6:1321-1325.). A recombinant clone was used to transform *Escherichia coli* strain BL21-DE3 which harbors a plasmid that has an isopropyl-ß-D-thiogalactopyranoside (IPTG)-inducible promoter preceding the gene encoding T7 polymerase. Induction with IPTG leads to high levels of T7 polymerase expression, which is necessary for expression of the recombinant protein in pET-11d, which has a T7 promoter. The pET-11d containing the *Lol p* V (clone 12R) was confirmed by dideoxy sequencing (Sanger et al., (1977) *Proc. Natl. Acad. Sci.*, (USA) 74:5460-5463) to be a *Lol p* V clone in the correct reading frame for expression.

The pET-11d *Lol p* V clone was grown on a large scale for recombinant protein expression and purification. A 2 ml culture of bacteria containing the recombinant plasmid was grown for 8 hr, then streaked onto solid media (e.g. 6 petri plates (100 x 15 mm) with 1.5% agarose in LB medium (Gibco-BRL, Gaithersburg, MD) containing 200 µg/ml ampicillin), grown to confluence overnight, then scraped into 9 L of liquid media (Brain Heart Infusion media, Difco) containing ampicillin (200 µg/ml). The culture was grown until the A_{600} was 1.0, IPTG added (1 mM final concentration), and the culture grown for an additional 2 hours.

Bacteria were recovered by centrifugation (7,930 x g, 10 min), and lysed in 90 ml of 6M Guanidine-HCl, 0.1M Na_2HPO_4, pH 8.0 for 1 hour with vigorous shaking. Insoluble material was removed by centrifugation (11,000 x g, 10 min, 4° C). The pH of the lysate was adjusted to pH 8.0, and the lysate applied to an 80 ml Nickel NTA agarose column (Qiagen, Chatsworth, CA) that had been equilibrated with 6 M Guanidine HCl, 100 mM Na_2HPO_4, pH 8.0. The column was sequentially washed with 6 M Guanidine HCl, 100 mM Na_2HPO_4, 10 mM Tris-HCl, pH 8.0, then 8 M urea, 100 mM Na_2HPO_4, pH 8.0, and finally 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCl, pH 6.3. The column was washed with each buffer until the flow through had an $A_{280} \leq 0.05$.

The recombinant protein, r*Lol p* V, was eluted with 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCl, pH 4.5, and collected in 10 ml aliquots. The protein concentration of each fraction was determined by absorbance at A_{280} and the peak fractions pooled. An aliquot of the collected recombinant protein was analyzed on SDS-PAGE (data not shown) according to the method in Sambrook et al., *supra.*

The first 9 liter preparation yielded 12 mg of rLol p V with approximately 60-70% purity. Purity of the preparation was determined by densitometry (Shimadzu Flying Spot

Scanner, Shimadzu Scientific Instruments, Inc., Braintree, MA) of the coomassie-blue stained SDS-PAGE gel.

Example 5- Cloning and Expression of *Dac g* V

Dactylis glomerata pollen was purchased from Greer Laboratories (Lenoir, NC). RNA was isolated as previously described in PCT/US92/05661 (WO93/01213) and polyA+ RNA was isolated using MICRO-FAST TRACK® mRNA isolation kit from Invitrogen (San Diego,CA). Double stranded cDNA was made with the BRL cDNA SYNTHESIS PLUS® kit (Gaithersburg,MD). A cDNA library was made in λgt10 using the cDNA CLONING SYSTEM-lGT10® (Amersham, Arlington Heights, IL). The *D. glomerata* double stranded cDNA was ligated with adaptor arms, containing *Eco* RI, *Bam* HI, *Kpn* I and *Nco* I restriction sites and ligated into λgt10 vector arms using the manufacturer's suggested protocols. The library was packaged and titred also using the manufacturer's suggested protocols. The library was plated out and over 100,000 independent phage plaques were screened using random primed (RANDOM PRIMED DNA LABELING KIT®, Boehringer Mannheim Corporation, Indianopolis, IN) or nick-translated probe [Sambrook J et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The library was screened with the 1.2 kb *Lol p* V clone 12R cDNA (SEQ ID NO:1) [Singh MB et al, *Proc Natl Acad Sci USA*, 1991; 88: 1384-1388].

There were many positive clones identified in the first screen. Several clones were picked using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989] and dilutions of high-titred phage stocks were re-screened using the same *Lol p* V clone 12R probe. The phage stocks were prepared using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. Positive clones were again picked, high-titred stocks prepared as before and serial dilutions were prepared for tertiary screening with the *Lol p* V clone 12R probe. Six phage clones, 228, 235, 236, 259, 267, and 285, were positive after this tertiary screening and high titred stocks were prepared as described [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The cDNA inserts were isolated from the selected phage using standard techniques [Sambrook J et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989]. The insert from clone 228 was approximately 500 base pairs

(bp). The insert from clone 235 was approximately 1,000 bp. The insert from clone 236 was approximately 1200 bp. The insert from clone 259 was approximately 1,200 bp. The insert from clone 267 was approximately 1,000 bp. The insert from clone 285 was approximately 800 bp. The isolated inserts were cloned into appropriately digested pUC18 and/or pUC19 for subsequent analysis. The cDNA inserts were sequenced using the SEQUENASE® kits (USB, Cleveland, OH) based on the standard dideoxy chain termination method of Sanger *et al.* [Sanger F et al. *Proc Natl Acad Sci USA*, 1977; **74**: 5460-5463].

Partial sequences for all of the clones were determined. All were found to contain *Dac g* V sequences by comparison with *Lol p* V clone 12R sequence (SEQ ID NO:1) [Ong EK et al. *Gene*, 1993; **134**: 235-240]. The partial translated sequences of clones 235 and 236 were very similar to each other, although they started at different sites in the sequence (not shown), and appear to represent one isoform of *Dac g* V. The partial translated sequence of clone 259 was different from that of clones 235 and 236 and appear to represent a second isoform of *Dac g* V. The partial translated sequence of clone 259 is most homologous to the sequence of *Lol p* V clone 12R (SEQ ID NO:2) [Ong EK et al. *Gene* 1993; **134**: 235-240]. The partial translated sequences of clones 235 and 236 are most closely homologous to the sequence of *Lol p* V clone 19R [Ong EK et al. *Gene* 1993; **134**: 235-240].

Clone 259 was sequenced in its entirety. It was sequenced from both ends using standard forward and reverse primers (New England Biolabs, Beverly, MA). Subconstructs were prepared by digestion of isolated insert with *Eco* RI and *Pst* I and the fragments were cloned into appropriately digested pUC18 for internal sequencing. The *Eco* RI/*Pst* I insert that corresponded to the 5' portion of the *Dac g* V gene was isolated and further digested with *Stu* I or *Sau* 3A and *Xho* I and ligated into appropriately digested pUC19 for further sequence analysis. The nucleotide (SEQ ID NO:57) and deduced amino acid (SEQ ID NO:58) sequence of clone 259 is shown in Figure 16. Nucleotides 1-25 correspond to adaptor sequence. The sequence ends with the poly A tract; the adaptor sequence is not shown at the 3' end of the sequence. The nucleotide sequence from 700 to 1181 is only preliminary and some bases may be misidentified. For example, nucleotide 712 has been tentatively identified as a "C". However, this is the third position of the codon encoding Gly196 and the presence of another nucleotide at residue 712 would not change the predicted amino acid. It is difficult to sequence the Group V grass allergens due to their high GC content.

Clone 236 and 259 have been deposited with the ATCC.

As Group V allergens tend to have very conserved regions, the major T cell epitope containing peptides of *Lol p* V as described herein, are likely to be the major T cell epitopes of *Dac g* V, particularly where the regions are highly conserved between the related grasses.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Griffith, Irwin J.
Kuo, Mei-Chang
Luqman, Mohammad

(ii) TITLE OF INVENTION: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

(iii) NUMBER OF SEQUENCES: 58

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: IMMULOGIC PHARMACEUTICAL CORPORATION
(B) STREET: 610 Lincoln Street
(C) CITY: Waltham
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02154

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII Text

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/106,016
(B) FILING DATE: 13-AUG-1993
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Darlene A. Vanstone
(B) REGISTRATION NUMBER: 35,729
(C) REFERENCE/DOCKET NUMBER: 075.1 PCT

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 466-6000
(B) TELEFAX: (617) 466-6040

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1229 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 40..942

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 115..940

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
CGCTATCCCT CCCTCGTACA AACAAACGCA AGAGCAGCA ATG GCC GTC CAG AAG
54
                                                Met Ala Val Gln Lys
                                                -25

TAC ACG GTG GCT CTA TTC CTC GCC GTG GCC CTC GTG GCG GGC CCG GCC
102
Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu Val Ala Gly Pro Ala
-20                 -15                 -10                 -5

GCC TCC TAC GCC GCT GAC GCC GGC TAC ACC CCC GCA GCC GCG GCC ACC
150
Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Thr Pro Ala Ala Ala Ala Thr
                1                   5                  10

CCG GCT ACT CCT GCT GCC ACC CCG GCT GCG GCT GGA GGG AAG GCG ACG
198
Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala Gly Gly Lys Ala Thr
          15                  20                  25

ACC GAC GAG CAG AAG CTG CTG GAG GAC GTC AAC GCT GGC TTC AAG GCA
246
Thr Asp Glu Gln Lys Leu Leu Glu Asp Val Asn Ala Gly Phe Lys Ala
     30                  35                  40

GCC GTG GCC GCC GCT GCC AAC GCC CCT CCG GCG GAC AAG TTC AAG ATC
294
Ala Val Ala Ala Ala Ala Asn Ala Pro Pro Ala Asp Lys Phe Lys Ile
 45                  50                  55                  60

TTC GAG GCC GCC TTC TCC GAG TCC TCC AAG GGC CTC CTC GCC ACC TCC
342
Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser
                65                  70                  75

GCC GCC AAG GCA CCC GGC CTC ATC CCC AAG CTC GAC ACC GCC TAC GAC
390
Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys Leu Asp Thr Ala Tyr Asp
            80                  85                  90

GTC GCC TAC AAG GCC GCC GAG GGC GCC ACC CCC GAG GCC AAG TAC GAC
438
Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp
          95                 100                 105

GCC TTC GTC ACT GCC CTC ACC GAA GCG CTC CGC GTC ATC GCC GGC GCC
486
Ala Phe Val Thr Ala Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala
     110                 115                 120

CTC GAG GTC CAC GCC GTC AAG CCC GCC ACC GAG GAG GTC CCT GCT GCT
534
Leu Glu Val His Ala Val Lys Pro Ala Thr Glu Glu Val Pro Ala Ala
125                 130                 135                 140

AAG ATC CCC ACC GGT GAG CTG CAG ATC GTT GAC AAG ATC GAT GCT GCC
582
Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp Lys Ile Asp Ala Ala
                145                 150                 155
```

TTC AAG ATC GCA GCC ACC GCC GCC AAC GCC GCC CCC ACC AAC GAT AAG
630
Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys
160 165 170

TTC ACC GTC TTC GAG AGT GCC TTC AAC AAG GCC CTC AAT GAG TGC ACG
678
Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala Leu Asn Glu Cys Thr
175 180 185

GGC GGC GCC TAT GAG ACC TAC AAG TTC ATC CCC TCC CTC GAG GCC GCG
726
Gly Gly Ala Tyr Glu Thr Tyr Lys Phe Ile Pro Ser Leu Glu Ala Ala
190 195 200

GTC AAG CAG GCC TAC GCC GCC ACC GTC GCC GCC GCG CCC GAG GTC AAG
774
Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Glu Val Lys
205 210 215 220

TAC GCC GTC TTT GAG GCC GCG CTG ACC AAG GCC ATC ACC GCC ATG ACC
822
Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr
225 230 235

CAG GCA CAG AAG GCC GGC AAA CCC GCT GCC GCC GCT GCC ACA GGC GCC
870
Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala Ala Ala Ala Thr Gly Ala
240 245 250

GCA ACC GTT GCC ACC GGC GCC GCA ACC GCC GCC GCC GGT GCT GCC ACC
918
Ala Thr Val Ala Thr Gly Ala Ala Thr Ala Ala Ala Gly Ala Ala Thr
255 260 265

GCC GCT GCT GGT GGC TAC AAA GCC TGATCAGCTT GCTAATATAC TACTGAACGT
972
Ala Ala Ala Gly Gly Tyr Lys Ala
270 275

ATGTATGTGC ATGATCCGGG CGGCGAGTGG TTTTGTTGAT AATTAATCTT CGTTTTCGTT
1032

TCATGCAGCC GCGATCGAGA GGGCTTGCAT GCTTGTAATA ATTCAATATT TTTCATTTCT
1092

TTTTGAATCT GTAAATCCCC ATGACAAGTA GTGGGATCAA GTCGGCATGT ATCACCGTTG
1152

ATGCGAGTTT AACGATGGGG AGTTTATCAA AGAATTTATT ATTAAAAAAA AAAAAAAAAA
1212

AAAAAAAAAA AAAAAAA
1229

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 301 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu
-25                 -20                 -15                 -10

Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Thr Pro
                -5                  1                   5

Ala Ala Ala Ala Thr Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala
        10                  15                  20

Gly Gly Lys Ala Thr Thr Asp Glu Gln Lys Leu Leu Glu Asp Val Asn
    25                  30                  35

Ala Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Asn Ala Pro Pro Ala
40                  45                  50                  55

Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly
                60                  65                  70

Leu Leu Ala Thr Ser Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys Leu
            75                  80                  85

Asp Thr Ala Tyr Asp Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro
        90                  95                  100

Glu Ala Lys Tyr Asp Ala Phe Val Thr Ala Leu Thr Glu Ala Leu Arg
    105                 110                 115

Val Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Ala Thr Glu
120                 125                 130                 135

Glu Val Pro Ala Ala Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp
                140                 145                 150

Lys Ile Asp Ala Ala Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala Ala
            155                 160                 165

Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala
        170                 175                 180

Leu Asn Glu Cys Thr Gly Gly Ala Tyr Glu Thr Tyr Lys Phe Ile Pro
    185                 190                 195

Ser Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala
200                 205                 210                 215

Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala
                220                 225                 230

Ile Thr Ala Met Thr Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala Ala
            235                 240                 245

Ala Ala Thr Gly Ala Ala Thr Val Ala Thr Gly Ala Ala Thr Ala Ala
        250                 255                 260

Ala Gly Ala Ala Thr Ala Ala Ala Gly Gly Tyr Lys Ala
    265                 270                 275
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Asp Ala Gly Tyr Thr Pro Ala Ala Ala Thr Pro Ala Thr Pro
1 5 10 15

Ala Ala Thr Pro
20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala Thr Pro Ala Thr Pro Ala Ala Thr Pro Ala Ala Ala Gly Gly Lys
1 5 10 15

Ala Thr Thr Asp
20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Ala Ala Gly Gly Lys Ala Thr Thr Asp Glu Gln Lys Leu Leu Glu
1 5 10 15

Asp Val Asn Ala
20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Glu Gln Lys Leu Leu Glu Asp Val Asn Ala Gly Phe Lys Ala Ala Val
1 5 10 15

Ala Ala Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Asn Ala Pro Pro Ala Asp
1 5 10 15

Lys Phe Lys Ile
20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asn Ala Pro Pro Ala Asp Lys Phe Lys Ile Phe Glu Ala Ala Phe Ser
1 5 10 15

Glu Ser Ser Lys
20

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Phe Glu Ala Ala Phe Ser Glu Ser Ser Lys Gly Leu Leu Ala Thr Ser
1 5 10 15

Ala Ala Lys Ala
20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Gly Leu Leu Ala Thr Ser Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys
1 5 10 15

Leu Asp Thr Ala
20

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Pro Gly Leu Ile Pro Lys Leu Asp Thr Ala Tyr Asp Val Ala Tyr Lys
1 5 10 15

Ala Ala Glu Gly
20

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Tyr Asp Val Ala Tyr Lys Ala Ala Glu Gly Ala Thr Pro Glu Ala Lys
1 5 10 15

Tyr Asp Ala Phe
20

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ala Thr Pro Glu Ala Lys Tyr Asp Ala Phe Val Thr Ala Leu Thr Glu
1 5 10 15

Ala Leu Arg Val
20

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Val Thr Ala Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala Leu Glu
1 5 10 15

Val His Ala Val
20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Ala Thr Glu Glu
1 5 10 15

Val Pro Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Lys Pro Ala Thr Glu Glu Val Pro Ala Ala Lys Ile Pro Thr Gly Glu
1 5 10 15

Leu Gln Ile Val
20

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp Lys Ile Asp Ala Ala
1 5 10 15

Phe Lys Ile Ala
20

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Asp Lys Ile Asp Ala Ala Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala
1 5 10 15

Ala Pro Thr Asn
20

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe
1 5 10 15

Glu Ser Ala Phe
20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala Leu Asn Glu
1 5 10 15

Cys Thr Gly Gly
20

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Asn Lys Ala Leu Asn Glu Cys Thr Gly Gly Ala Tyr Glu Thr Tyr Lys
1 5 10 15

Phe Ile Pro Ser
20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ala Tyr Glu Thr Tyr Lys Phe Ile Pro Ser Leu Glu Ala Ala Val Lys
1 5 10 15

Gln Ala Tyr Ala
20

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala
1 5 10 15

Pro Glu Val Lys
20

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Ala Thr Val Ala Ala Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Ala
1 5 10 15

Ala Leu Thr Lys
20

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Thr
1 5 10 15

Gln Ala Gln Lys
20

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ala Ile Thr Ala Met Thr Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala
1 5 10 15

Ala Ala Ala Thr
20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Ala Gly Lys Pro Ala Ala Ala Ala Ala Thr Gly Ala Ala Thr Val Ala
1 5 10 15

Thr Gly Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Gly Ala Ala Thr Val Ala Thr Gly Ala Ala Thr Ala Ala Ala Gly Ala
1 5 10 15

Ala Thr Ala Ala
20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Thr Ala Ala Ala Gly Ala Ala Thr Ala Ala Ala Gly Gly Tyr Lys Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Glu Tyr Gly Asp
1 5 10 15

Lys Trp Leu Asp
20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Ile Ala Lys Val Xaa Pro Gly Xaa Asn Ile Thr Ala Glu Tyr Gly Asp
1 5 10 15

Lys Trp Leu Asp
20

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr
1 5 10 15

Gly Lys Pro Thr
20

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asn Val
1 5 10 15

Asp Lys Ala Pro
20

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val
1 5 10 15

Asp Lys Ala Pro
20

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly
1 5 10 15

Cys Gly Asn Thr
20

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly
1 5 10 15

Arg Gly Cys Gly
20

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Pro Ile Phe Lys Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys
1 5 10 15

Cys Thr Lys Pro
20

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly Glu
1 5 10 15

Ala Val Thr Val
20

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Glu Ser Cys Ser Gly Glu Ala Val Thr Val Thr Ile Thr Asp Asp Asn
1 5 10 15

Glu Glu Pro Ile
20

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Thr Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Pro Tyr His Phe Asp
1 5 10 15

Leu Ser Gly His
20

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala
1 5 10 15

Asp Asp Gly Glu
20

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Ala Phe Gly Ser Met Ala Asp Asp Gly Glu Glu Gln Lys Leu Arg Ser
1 5 10 15

Ala Gly Glu Leu
20

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Glu Gln Lys Leu Arg Ser Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg
1 5 10 15

Val Lys Cys Lys
20

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp Asp Thr Lys
1 5 10 15

Pro Thr Phe His
20

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys Ala Ser Asn
1 5 10 15

Pro Asn Tyr Leu
20

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Val Glu Lys Ala Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr
1 5 10 15

Val Asp Gly Asp
20

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr
1 5 10 15

Val Asp Gly Asp
20

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ala Ile Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val
1 5 10 15

Asp Ile Lys Glu
20

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp
1 5 10 15

Ile Glu Leu Lys
20

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Val
1 5 10 15

Trp Arg Ile Asp
20

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu
1 5 10 15

Gly Gly Thr Lys
20

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val
1 5 10 15

Ile Pro Glu Gly
20

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser
1 5 10 15

Tyr Ser Ala Lys
20

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Ala Asp Ala Gly Tyr Thr Hyp Ala Ala Ala Ala Thr Hyp Ala Thr Hyp
1 5 10 15

Ala Ala Thr Hyp Ala Ala Ala Gly Gly Lys Ala Thr Thr Asp Glu Gln
20 25 30

Lys

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp
1 5 10 15

Asn Gly Gly Ala
20

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr
1 5 10 15

Gly Pro Phe Thr
20

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1181 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 53..124

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 125..961

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

```
GAATTCGAGG ATCCGGGTAC CATGGCTCCG ACAAACCAAC GCAAGAGCAG CA ATG
55
                                                              Met

GCA GTG CAG CAG TAC ACG GTG GCG CTG TTC CTG GCC GTG GCC TCG TGT
103
Ala Val Gln Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Ser Cys
            -20                 -15                 -10

CGG GCC CGC GCC TCC TAC GCC GCC GAC GCC GGC TAC GCC CCC GCC ACT
151
Arg Ala Arg Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro Ala Thr
        -5                  1                   5

CCC GCC ACC CCG GCT ACC CCC GCG GCC CCA GGC GCA GCG GTG CCA GCA
199
Pro Ala Thr Pro Ala Thr Pro Ala Ala Pro Gly Ala Ala Val Pro Ala
 10                  15                  20                  25

GGG AAG GCG GCG ACC GAG GAG CAG AAG CTG ATC GAG AAG ATC AAC GCC
247
Gly Lys Ala Ala Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala
                30                  35                  40

GGC TTC AAG GCC GCC GTG GCG GCC GCC GCG GGC GTC CCG CCA GGC GAC
295
Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Gly Val Pro Pro Gly Asp
            45                  50                  55

AAG TAC AAG ACG TTC GTC GAA ACC TTC GGC AAG GCC TCC AAC AAG GCC
343
Lys Tyr Lys Thr Phe Val Glu Thr Phe Gly Lys Ala Ser Asn Lys Ala
        60                  65                  70

TTC CTG GGG GAC CTC CCG ACC AAC TAC GCC GAT GTC AAC TCC AGG GCC
391
Phe Leu Gly Asp Leu Pro Thr Asn Tyr Ala Asp Val Asn Ser Arg Ala
 75                  80                  85

CAG CTC ACC TCG AAG CTC GAC GCC GCC TAC AAG CTC GCC TAC GAC GCC
439
Gln Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Asp Ala
 90                  95                  100                 105

GCC CAG GGC GCC ACC CCC GAG GCC AAG TAC GAC GCC TAC GTC GCC ACC
487
Ala Gln Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr
                110                 115                 120
```

```
CTC AGC GAG GCG CTC CGC ATC ATC GCC GGC ACC CTC GAG GTC CAC GCC
535
Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala
            125                 130                 135

GTC AAG CCC GCT GCC GAG GAG GTC AAG CCT ATC CCC GCC GGA GAG CTG
583
Val Lys Pro Ala Ala Glu Glu Val Lys Pro Ile Pro Ala Gly Glu Leu
        140                 145                 150

CAG ATC GTC GAC AAG ATT GAC GTC GCC TTC AGA ACT GCC GCC ACC GCC
631
Gln Ile Val Asp Lys Ile Asp Val Ala Phe Arg Thr Ala Ala Thr Ala
    155                 160                 165

GCC AAC GCC GCC CCC ACC AAC GAC AAG TTC ACC GTA TTC GAG ACC ACC
679
Ala Asn Ala Ala Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Thr Thr
170                 175                 180                 185

TTT AAC AAG GCC ATC AAG GAG AGC ACG GGC GGC ACC TAC GAG AGC TAC
727
Phe Asn Lys Ala Ile Lys Glu Ser Thr Gly Gly Thr Tyr Glu Ser Tyr
                190                 195                 200

AAG TTC ATT CCC ACC CTT GAG GCC GCC GTT AAG CAG GCC TAC GCC GCC
775
Lys Phe Ile Pro Thr Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala
            205                 210                 215

ACC GTC GCA TCC GCG CCG GAG GTC AAG TAC GCC GTC TTT GAG ACC GCG
823
Thr Val Ala Ser Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Thr Ala
        220                 225                 230

CTG AAA AAG GCG GTC ACC GCC ATG TCC GAG GCC CAG AAG GAA GCC AAG
871
Leu Lys Lys Ala Val Thr Ala Met Ser Glu Ala Gln Lys Glu Ala Lys
    235                 240                 245

CCC GCC ACC GCC ACC CCG ACC CCC ACC GCA ACT GCC GCG GCC GCG GTG
919
Pro Ala Thr Ala Thr Pro Thr Pro Thr Ala Thr Ala Ala Ala Ala Val
250                 255                 260                 265

GCC ACC AAC GCC GCC CCC GTC GCT GCT GGT GGC TAC AAA ATC
961
Ala Thr Asn Ala Ala Pro Val Ala Ala Gly Gly Tyr Lys Ile
                270                 275

TGATCAACTC GCTAGCAATA TACACATCCA TCATGCACAT ATAGAGCTGT GTATGTATGT
1021

GCATGCATGC CGTGGCGCCG CGCAAGTTTG CTCATAATTA ATTCTTGGTT TTCGTTGCTT
1081

GCATCCACGA GCGACCGAGC CCGTGGATAG TCGCATGTGT ATGTAATTTT TTCTGAGAAA
1141

TGTGTATATG TAATATATAA TTGAGTACTA AAAAAAAAAA
1181
```

(2) INFORMATION FOR SEQ ID NO 58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 279 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro
1 5 10 15

Ala Ala Pro Gly Ala Ala Val Pro Ala Gly Lys Ala Ala Thr Glu Glu
20 25 30

Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Val Ala
35 40 45

Ala Ala Ala Gly Val Pro Pro Gly Asp Lys Tyr Lys Thr Phe Val Glu
50 55 60

Thr Phe Gly Lys Ala Ser Asn Lys Ala Phe Leu Gly Asp Leu Pro Thr
65 70 75 80

Asn Tyr Ala Asp Val Asn Ser Arg Ala Gln Leu Thr Ser Lys Leu Asp
85 90 95

Ala Ala Tyr Lys Leu Ala Tyr Asp Ala Ala Gln Gly Ala Thr Pro Glu
100 105 110

Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile
115 120 125

Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu
130 135 140

Val Lys Pro Ile Pro Ala Gly Glu Leu Gln Ile Val Asp Lys Ile Asp
145 150 155 160

Val Ala Phe Arg Thr Ala Ala Thr Ala Ala Asn Ala Ala Pro Thr Asn
165 170 175

Asp Lys Phe Thr Val Phe Glu Thr Thr Phe Asn Lys Ala Ile Lys Glu
180 185 190

Ser Thr Gly Gly Thr Tyr Glu Ser Tyr Lys Phe Ile Pro Thr Leu Glu
195 200 205

Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ser Ala Pro Glu
210 215 220

Val Lys Tyr Ala Val Phe Glu Thr Ala Leu Lys Lys Ala Val Thr Ala
225 230 235 240

Met Ser Glu Ala Gln Lys Glu Ala Lys Pro Ala Thr Ala Thr Pro Thr
245 250 255

Pro Thr Ala Thr Ala Ala Ala Ala Val Ala Thr Asn Ala Ala Pro Val
260 265 270

Ala Ala Gly Gly Tyr Lys Ile
275

Claims

What is claimed is:

1. An isolated peptide of *Lol p* V wherein said peptide comprises at least one T cell epitope of *Lol p* V, said peptide comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in Fig. 2 of peptides LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

2. An isolated peptide of claim 1, said peptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences as shown in Fig. 2 of peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28).

3. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index of at least 2.0.

4. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index approximately equivalent to or greater than the T cell stimulation index of said isolated peptide from which it is derived.

5. An isolated peptide of claim 1 which, when administered to an individual sensitive to *Lol p* V allergen, induces T cells to become nonresponsive or modifies the lymphokine secretion profile of T cells in the individual.

6. An isolated peptide of claim 2 which binds immunoglobulin E to a substantially lesser extent than native *Lol p* V binds immunoglobulin E.

7. An isolated nucleic acid sequence having a sequence encoding a peptide of claim 1.

8. A functional equivalent of a nucleic acid sequence encoding a peptide of claim 1.

9. An isolated peptide which is immunologically cross-reactive with T cells reactive with a peptide of claim 2.

10. An isolated peptide of *Lol p* V wherein said peptide has a T cell stimulation index of at least about 3.5.

11. An isolated peptide of claim 10 wherein said T cell stimulation index is at least about 5.

12. A peptide of claim 1 modified to improve solubility.

13. A peptide of claim 2 modified to improve solubility.

14. A modified peptide of claim 13 which does not bind immunoglobulin E specific for *Lol p V* in a substantial percentage of individuals sensitive to *Lol p V*, or if binding of the peptide to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to *Lol p V*.

15. A modified peptide of claim 12 which modifies, in an individual sensitive to *Lol p* V to whom it is administered, the allergic response of the individual to a *Lol p* V allergen.

16. A monoclonal antibody specifically reactive with a peptide of claim 1.

17. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 7.

18. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 8.

19. An expression vector comprising a nucleic acid sequence coding for a peptide of claim 1.

20. An expression vector comprising the functional equivalent of a nucleic acid sequence coding for a peptide of claim 1.

21. A composition comprising at least one isolated peptide of claim 1 and a pharmaceutically acceptable carrier or diluent.

22. A composition of claim 21 comprising a combination of peptides selected from the group of combinations consisting of:
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO: 13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO: 10), LPIX-9 (SEQ ID NO: 11), LPIX-11 (SEQ ID NO: 13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO: 21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28);

LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22);
LPIX-4 (SEQ ID NO:6), LPIX-20 (SEQ ID NO:22);
LPIX-5 (SEQ ID NO:7), and LPIX-20 (SEQ ID NO:22);
LPIX-6 (SEQ ID NO:8), and LPIX-20 (SEQ ID NO:22);
LPIX-11 (SEQ ID NO: 13), and LPIX-20 (SEQ ID NO:22);
LPIX-12 (SEQ ID NO:14), and LPIX-20 (SEQ ID NO:22);
LPIX-16 (SEQ ID NO:18), and LPIX-20 (SEQ ID NO:22); and
LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22).

23. A composition comprising at least one isolated peptide of claim 13 and a pharmaceutically acceptable carrier or diluent.

24. A method of detecting sensitivity to *Lol p* V in an individual, *in vitro*, comprising combining a blood sample obtained from the individual with at least one peptide of claim 1, under conditions appropriate for binding of blood components with the peptide, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to ryegrass pollen.

25. A method of claim 24 wherein the extent to which binding occurs is determined by assessing B cell function, T cell function, T cell proliferation or a combination of T cell proliferation and B cell function.

26. A composition comprising a pharmaceutically acceptable carrier or diluent and at least two peptides of claim 1 wherein said composition comprises a sufficient percentage of the T cell epitopes of the *Lol p* V protein allergen such that upon administration of the composition to an individual sensitive to *Lol p* V, T cells of the individual become nonresponsive to said *Lol p V* protein allergen.

27. A peptide of claim 4 modified to improve solubility.

28. A composition comprising at least one isolated peptide of claim 27.

29. A composition comprising a pharmaceutically acceptable carrier or diluent and at least two peptides, each peptide comprising at least one T cell epitope, wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p* V which is selected from the group consisting of: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) (as shown in Fig. 2), and wherein at least one peptide comprises an amino acid sequence or portion thereof derived from *Lol p* I which is selected from the group consisting of: LPI-1

(SEQ ID NO:30), LPI-1.1 (SEQ ID NO:31), LPI-2 (SEQ ID NO:32), LPI-3 (SEQ ID NO:55), LPI-4 (SEQ ID NO:33), LPI-4.1 (SEQ. ID NO:34), LPI-5 (SEQ ID NO:35), LPI-6 (SEQ ID NO:36), LPI-7 (SEQ ID NO:37), LPI-8 (SEQ ID NO:38), LPI-9 (SEQ ID NO:39), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-12 (SEQ ID NO:42), LPI-13 (SEQ ID NO:43), LPI-14 (SEQ ID NO:44), LPI-15 (SEQ ID NO:45), LPI-16 (SEQ ID NO:46), LPI-16.1(SEQ ID NO:47), LPI-17 (SEQ ID NO:48), LPI-18 (SEQ ID NO:49), LPI-19 (SEQ ID NO:50), LPI-20 (SEQ ID NO:56), LPI-21 (SEQ ID NO:51), LPI-22 (SEQ ID NO:52), and LPI-23 (SEQ ID NO:53) (as shown in Fig. 3).

30. A composition of claim 29 comprising a combination of peptides selected from the group of combinations consisting of:

LPI-16.1, (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28); LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ. ID NO:45), LPI-22 (SEQ ID NO:52);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16

(SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-10 (SEQ ID NO:40), LPI-11 (SEQ ID NO:41), LPI-15 (SEQ ID NO:45), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPI-11 (SEQ ID NO:41), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPI-3 (SEQ ID NO:55), LPI-4.1 (SEQ ID NO:34), LPI-22 (SEQ ID NO:52), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), LPIX-26 (SEQ ID NO:28);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-9 (SEQ ID NO:11), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID

NO:8), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22);

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22); and

LPI-16.1 (SEQ ID NO:47), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56), LPI-23 (SEQ ID NO:53), LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22).

31. A composition comprising at least four, and no more than eight peptides, wherein at least two, and no more than four peptides are derived from *Lol p* V and are selected from the following group of *Lol p* V peptides: LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-11 (SEQ ID NO: 13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22), and wherein at least two, and no more than four peptides are derived from *Lol p* I and are selected from the following group of *Lol p* I peptides: LPI-16 (SEQ ID NO:46), LPI-18 (SEQ ID NO:49), LPI-20 (SEQ ID NO:56) and LPI-23 (SEQ ID NO:53).

32. A composition of claim 31 wherein two peptides are derived from *Lol p* I and three peptides are derived from *Lol p* V.

33. A composition of claim 31 wherein three peptides are derived from *Lol p* I and three peptides are derived from *Lol p* V

34. A composition of claim 31 wherein three peptides are derived from *Lol p* I and four peptides are derived from *Lol p* V.

35. A composition of claim 31 wherein four peptides are derived from *Lol p* I and four peptides are derived from *Lol p* V.

36. A composition of claim 31 wherein four peptides are derived from *Lol p* I and three peptides are derived from *Lol p* V.

37. Use of a composition of claims 21, 22, 23, 26, 28, 29, 30, or 31-36 in the manufacture of a medicament for use in treating sensitivity to *Lol p* V allergen or an immunologically cross-reactive allergen.

38. An isolated peptide of *Lol p* V, said peptide comprising at least one T cell epitope of *Lol p* V, said peptide having a positivity index of at least 60 and a mean T cell stimulation index of at least about 2.5 determined in a population of individuals sensitive to *Lol p* V.

39. An isolated peptide of claim 38 wherein said population of individuals is at least 15 individuals.

40. A portion of an isolated peptide of claim 38 wherein said portion has a positivity index of at least 60 and a mean T cell stimulation index of at least about 2.5 determined in a population of individuals sensitive to *Lol p* V.

41. An isolated peptide of claim 40 wherein said population of individuals is at least 15 individuals.

42. All or a portion of an isolated peptide of *Lol p I*, said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula X_n-Y-Z_m, wherein Y is an amino acid sequence selected from the group consisting of: LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29) wherein X_n are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein Z_m are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.

43. A portion of an isolated peptide of claim 42 wherein the portion comprises at least fifteen amino acid residues.

44. An isolated nucleic acid having a nucleotide sequence coding for *Dac g* I, or the functional equivalent of said nucleotide sequence.

45. An isolated nucleic acid sequence of claim 44 wherein said nucleotide sequence comprises the nucleotide sequence of Fig. 16.

46. An expression vector comprising a nucleotide sequence coding for *Dac g* I, or the functional equivalent of said nucleotide sequence.

47. A host cell transformed to express a protein encoded by the nucleic acid of claim 44.

48. Isolated *Dac g* I protein produced in a host cell transformed with the nucleic acid of claim 44.

```
CGCTATCCCTCCCTCGTACAAACAAACGCAAGAGCAGCAATGGCCGTCCAGAAGTACACG      60
                                                M  A  V  Q  K  Y  T
                                              -25              -20
GTGGCTCTATTCCTCGCCGTGGCCCTCGTGGCGGGCCCGGCCGCCTCCTACGCCGCTGAC     120
 V  A  L  F  L  A  V  A  L  V  A  G  P  A  A  S  Y  A  A  D
        -15              -10              -5               1
GCCGGCTACACCCCCGCAGCCGCGGCCACCCCGGCTACTCCTGCTGCCACCCCGGCTGCG     180
 A  G  Y  T  P  A  A  A  A  T  P  A  T  P  A  A  T  P  A  A
       5               10               15               20
GCTGGAGGGAAGGCGACGACCGACGAGCAGAAGCTGCTGGAGGACGTCAACGCTGGCTTC     240
 A  G  G  K  A  T  T  D  E  Q  K  L  L  E  D  V  N  A  G  F
      25               30               35               40
AAGGCAGCCGTGGCCGCCGCTGCCAACGCCCCTCCGGCGGACAAGTTCAAGATCTTCGAG     300
 K  A  A  V  A  A  A  A  N  A  P  P  A  D  K  F  K  I  F  E
      45               50               55               60
GCCGCCTTCTCCGAGTCCTCCAAGGGCCTCCTCGCCACCTCCGCCGCCAAGGCACCCGGC     360
 A  A  F  S  E  S  S  K  G  L  L  A  T  S  A  A  K  A  P  G
      65               70               75               80
CTCATCCCCAAGCTCGACACCGCCTACGACGTCGCCTACAAGGCCGCCGAGGGCGCCACC     420
 L  I  P  K  L  D  T  A  Y  D  V  A  Y  K  A  A  E  G  A  T
      85               90               95              100
CCCGAGGCCAAGTACGACGCCTTCGTCACTGCCCTCACCGAAGCGCTCCGCGTCATCGCC     480
 P  E  A  K  Y  D  A  F  V  T  A  L  T  E  A  L  R  V  I  A
     105              110              115              120
GGCGCCCTCGAGGTCCACGCCGTCAAGCCCGCCACCGAGGAGGTCCCTGCTGCTAAGATC     540
 G  A  L  E  V  H  A  V  K  P  A  T  E  E  V  P  A  A  K  I
     125              130              135              140
```

Fig. 1

```
CCCACCGGTGAGCTGCAGATCGTTGACAAGATCGATGCTGCCTTCAAGATCGCAGCCACC    600
 P  T  G  E  L  Q  I  V  D  K  I  D  A  A  F  K  I  A  A  T
    145            150            155            160
GCCGCCAACGCCGCCCCCACCAACGATAAGTTCACCGTCTTCGAGAGTGCCTTCAACAAG    660
 A  A  N  A  A  P  T  N  D  K  F  T  V  F  E  S  A  F  N  K
    165            170            175            180
GCCCTCAATGAGTGCACGGGCGGCGCCTATGAGACCTACAAGTTCATCCCCTCCCTCGAG    720
 A  L  N  E  C  T  G  G  A  Y  E  T  Y  K  F  I  P  S  L  E
    185            190            195            200
GCCGCGGTCAAGCAGGCCTACGCCGCCACCGTCGCCGCCGCGCCCGAGGTCAAGTACGCC    780
 A  A  V  K  Q  A  Y  A  A  T  V  A  A  A  P  E  V  K  Y  A
    205            210            215            220
GTCTTTGAGGCCGCGCTGACCAAGGCCATCACCGCCATGACCCAGGCACAGAAGGCCGGC    840
 V  F  E  A  A  L  T  K  A  I  T  A  M  T  Q  A  Q  K  A  G
    225            230            235            240
AAACCCGCTGCCGCCGCTGCCACAGGCGCCGCAACCGTTGCCACCGGCGCCGCAACCGCC    900
 K  P  A  A  A  A  A  T  G  A  A  T  V  A  T  G  A  A  T  A
    245            250            255            260
GCCGCCGGTGCTGCCACCGCCGCTGCTGGTGGCTACAAAGCCTGATCAGCTTGCTAATAT    960
 A  A  G  A  A  T  A  A  A  G  G  Y  K  A  *
    265            270            275
ACTACTGAACGTATGTATGTGCATGATCCGGGCGGCGAGTGGTTTTGTTGATAATTAATC   1020
TTCGTTTTCGTTTCATGCAGCCGCGATCGAGAGGGCTTGCATGCTTGTAATAATTCAATA   1080
TTTTTCATTTCTTTTTGAATCTGTAAATCCCCATGACAAGTAGTGGGATCAAGTCGGCAT   1140
GTATCACCGTTGATGCGAGTTTAACGATGGGGAGTTTATCAAAGAATTTATTATTAAAAA   1200
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA                                  1229
```

Fig. 1 cont.

LIX-1	ADAGYTXAAAATXATXAATX
LIX-1.1	ADAGYTPAAAATPATPAATP
LIX-2	ATXATXAATXAAAGGKATTD
LIX-2.1	ATPATPAATPAAAGGKATTD
LIX-3	AAAGGKATTDEQKLLEDVNA
LIX-4	EQKLLEDVNAGFKAAVAAAA
LIX-5	GFKAAVAAAANAPPADKFKI
LIX-6	NAPPADKFKIFEAAFSESSK
LIX-7	FEAAFSESSKGLLATSAAKA
LIX-8	GLLATSAAKAPGLIPKLDTA
LIX-9	PGLIPKLDTAYDVAYKAAEG
LIX-10	YDVAYKAAEGATPEAKYDAF
LIX-11	ATPEAKYDAFVTALTEALRV
LIX-12	VTALTEALRVIAGALEVHAV
LIX-13	IAGALEVHAVKPATEEVPAA
LIX-14	KPATEEVPAAKIPTGELQIV
LIX-15	KIPTGELQIVDKIDAAFKIA
LIX-16	DKIDAAFKIAATAANAAPTN
LIX-17	ATAANAAPTNDKFTVFESAF
LIX-18	DKFTVFESAFNKALNECTGG
LIX-19	NKALNECTGGAYETYKFIPS
LIX-20	AYETYKFIPSLEAAVKQAYA
LIX-21	LEAAVKQAYAATVAAAPEVK
LIX-22	ATVAAAPEVKYAVFEAALTK
LIX-23	YAVFEAALTKAITAMTQAQK
LIX-24	AITAMTQAQKAGKPAAAAAT
LIX-25	AGKPAAAAATGAATVATGAA
LIX-26	GAATVATGAATAAAGAATAA
LIX-27	TAAAGAATAAAGGYKA

X REPRESENTS HYDROXYPROLINE RESIDUE

Fig. 2

PEPTIDE NAME	PEPTIDE SEQUENCE
LPI-1	IAKVPPGPNITAEYGDKWLD
LPI-1.1	IAKVXPGXNITAEYGDKWLD
LPI-2	TAEYGDKWLDAKSTWYGKPT
LPI-3	AKSTWYGKPTGAGPKDNGGA
LPI-4	GAGPKDNGGACGYKNVDKAP
LPI-4.1	GAGPKDNGGACGYKDVDKAP
LPI-5	CGYKDVDKAPFNGMTGCGNT
LPI-6	FNGMTGCGNTPIFKDGRGCG
LPI-7	PIFKDGRGCGSCFEIKCTKP
LPI-8	SCFEIKCTKPESCSGEAVTV
LPI-9	ESCSGEAVTVTITDDNEEPI
LPI-10	TITDDNEEPIAPYHFDLSGH
LPI-11	APYHFDLSGHAFGSMADDGE
LPI-11.1	APYHFDLSGHAFGSMAKKGE
LPI-12	AFGSMADDGEEQKLRSAGEL
LPI-12.1	AFGSMAKKGEEQKLRSAGEL
LPI-13	EQKLRSAGELELQFRRVKCK
LPI-14	ELQFRRVKCKYPDDTKPTFH
LPI-15	YPDDTKPTFHVEKASNPNYL
LPI-16	VEKASNPNYLAILVKYVDGD
LPI-16.1	VEKGSNPNYLAILVKYVDGD
LPI-17	AILVKYVDGDGDVVAVDIKE
LPI-18	GDVVAVDIKEKGKDKWIELK
LPI-19	KGKDKWIELKESWGAVWRID
LPI-20	ESWGAVWRIDTPDKLTGPFT
LPI-21	TPDKLTGPFTVRYTTEGGTK
LPI-22	VRYTTEGGTKSEVEDVIPEG
LPI-23	SEVEDVIPEGWKADTSYSAK

Fig. 3


LP IX 27
2.8 (5.2%)
LP IX 26
3.0 (15.7%)
LP IX 25
LP IX 24
2.0 (5.2%)
LP IX 23
2.6 (10.5%)
LP IX 22
2.2 (6.3%)
LP IX 21
3.4 (10.5%)
LP IX 20
3.0 (36.8%)
LP IX 19
8.8 (10.5%)
LP IX 18
2.4 (5.2%)
LP IX 17
11.7 (31.5%)
LP IX 16
3.7 (31.5%)
LP IX 15
3.3 (10.5%)
LP IX 14
2.3 (5.2%)
LP IX 13
2.3 (10.5%)
LP IX 12
3.7 (21.0%)
LP IX 11
3.4 (10.5%)
LP IX 10
2.1 (5.1%)
LP IX 9
4.17 (15.7%)
LP IX 8
7.9 (5.2%)
LP IX 7
2.3 (10.5%)
LP IX 6
3.0 (36.8%)
LP IX 5
5.8 (26.3%)
LP IX 4
6.3 (26.3%)
LP IX 3
2.5 (10.5%)
LP IX 2.1
2.2 (10.5%)
LP IX 2
2.0 10.5%)
LP IX 1.1
2.4 (10.5%)
LP IX 1
2.3 (5.2%)
400
300
200
100
0
POSITIVITY INDEX

Fig. 4


2.8 (5.2%)
LP IX 27
3.0 (15.7%)
LP IX 26
LP IX 25
LP IX 24
2.6 (10.5%)
LP IX 23
LP IX 22
3.4 (10.5%)
LP IX 21
3.0 (36.8%)
LP IX 20
8.8 (10.5%)
LP IX 19
2.4 (5.2%)
LP IX 18
11.7 (31.5%)
LP IX 17
3.7 (31.5%)
LP IX 16
3.3 (10.5%)
LP IX 15
2.3 (5.2%)
LP IX 14
2.3 (10.5%)
LP IX 13
3.7 (21.0%)
LP IX 12
3.4 (10.5%)
LP IX 11
LP IX 10
4.17 (15.7%)
LP IX 9
7.9 (5.2%)
LP IX 8
2.3 (10.5%)
LP IX 7
3.0 (36.8%)
LP IX 6
5.8 (26.3%)
LP IX 5
6.3 (26.3%)
LP IX 4
2.5 (10.5%)
LP IX 3
2.2 (10.5%)
LP IX 2.1
LP IX 2
LP IX 1.1
2.3 (5.2%)
LP IX 1
40
30
20
10
0
RANKED SUM
OF 5 HIGHEST
PEPTIDE RESPONSES

Fig. 5


RYE GRASS POLLEN SPE
rLol p V
ABS 450nm
1.2
1.0
0.8
0.6
0.4
0.2
0.0
2
6
18
54
162
BACKGROUND
1/DILUTION

Fig. 6


RYE GRASS POLLEN SPE
rLol p V (12R)
BACKGROUND
162
54
18
6
2
1/DILUTION
2.5
2.0
1.5
1.0
0.5
0.0
ABS
450nm

Fig. 7


1118
1120
1125
1141
BACKGROUND
162
54
18
6
2
1/DILUTION
ABS
450nm
2.5
2.0
1.5
1.0
0.5
0.0

Fig. 8


1118
1120
1125
1141
2.5
2.0
1.5
1.0
0.5
0.0
ABS
450nm
2
6
18
54
162
BACKGROUND
1/DILUTION

Fig. 9


RYE GRASS POLLEN SPE
PURIFIED NATIVE Lol p V
rLol p V (12R)
NO COMPETING Ag
BACKGROUND
ABS 450nm
1.0
0.8
0.6
0.4
0.2
0.0
.01
.1
1
10
COMPETING Ag (µg/ml)

Fig. 10


Lol p SPE
PURIFIED NATIVE Lol p V
rLol p V (12R)
NO COMPETING Ag
BACKGROUND
ABS 450nm
2
1
0
.01
.1
1
10
CONCENTRATION OF PROTEIN IN µg/ml

Fig. 11


RYE GRASS POLLEN SPE
rLol p V (I2R)
BACKGROUND
% TOTAL RELEASE
80
60
40
20
0
.001
.01
.1
1
10
µg/ml ANTIGEN

Fig. 12


Lp IX-1
Lp IX-1.1
Lp IX-2
Lp IX-2.1
Lp IX-3
Lp IX-4
Lp IX-5
Lp IX-6
Lp IX-7
Lp IX-8
Lp IX-9
Lp IX-10
Lp IX-11
Lp IX-12
Lp IX-13
rLp V (12R)
BACKGROUND
1/DILUTION
2
10
50
ABS 450nm
0.0
0.5
1.0
1.5
2.0
2.5

Fig. 13A


Lp IX-14
Lp IX-15
Lp IX-16
Lp IX-17
Lp IX-18
Lp IX-19
Lp IX-20
Lp IX-21
Lp IX-22
Lp IX-23
Lp IX-24
Lp IX-25
Lp IX-26
Lp IX-27
rLp V (12R)
BACKGROUND
50
10
2
1/DILUTION
2.5
2.0
1.5
1.0
0.5
0.0
ABS
450nm

Fig. 13B


RYE GRASS POLLEN SPE
PURIFIED NATIVE Lol p I + Lol p V
rLol p I + rLol p V
NO COMPETING Ag
BACKGROUND
ABS 450nm
1.5
1.0
0.5
0.0
.01
.1
1
10
CONCENTRATION OF PROTEIN IN µg/ml

Fig. 14



Fig. 15

```
GAATTCGAGGATCCGGGTACCATGGCTCCGACAAACCAACGCAAGAGCAGCAATGGCA    58
                                                    M  A
                                                   -24
GTGCAGCAGTACACGGTGGCGCTGTTCCTGGCCGTGGCCTCGTGTCGGGCCCGCGCCTCC  118
 V  Q  Q  Y  T  V  A  L  F  L  A  V  A  S  C  R  A  R  A  S
    -20                                  -10
TACGCCGCCGACGCCGGCTACGCCCCCGCCACTCCCGCCACCCCGGCTACCCCCGCGGCC  178
 Y  A  A  D  A  G  Y  A  P  A  T  P  A  T  P  A  T  P  A  A
       1                                  10
CCAGGCGCAGCGGTGCCAGCAGGGAAGGCGGCGACCGAGGAGCAGAAGCTGATCGAGAAG  238
 P  G  A  A  V  P  A  G  K  A  A  T  E  E  Q  K  L  I  E  K
   20                                   30
ATCAACGCCGGCTTCAAGGCCGCCGTGGCGGCCGCCGCGGGCGTCCCGCCAGGCGACAAG  298
 I  N  A  G  F  K  A  A  V  A  A  A  A  G  V  P  P  A  D  K
   40                                   50
TACAAGACGTTCGTCGAAACCTTCGGCAAGGCCTCCAACAAGGCCTTCCTGGGGGACCTC  358
 Y  K  T  F  V  E  T  F  G  K  A  S  N  K  A  F  L  G  D  L
   60                                   70
CCGACCAACTACGCCGATGTCAACTCCAGGGCCCAGCTCACCTCGAAGCTCGACGCCGCC  418
 P  T  N  Y  A  D  V  N  S  R  A  Q  L  T  S  K  L  D  A  A
   80                                   90
TACAAGCTCGCCTACGACGCCGCCCAGGGCGCCACCCCCGAGGCCAAGTACGACGCCTAC  478
 Y  K  L  A  Y  D  A  A  Q  G  A  T  P  E  A  K  Y  D  A  Y
  100                                  110
```

Fig. 16

```
GTCGCCACCCTCAGCGAGGCGCTCCGCATCATCGCCGGCACCCTCGAGGTCCACGCCGTC  538
  V  A  T  L  S  E  A  L  R  R  I  I  A  G  T  L  E  V  H  A  V
                  120
AAGCCCCGCTGCCGAGGAGGTCAAGCCTATCCCCGCCGGAGAGCTGCAGATCGTCGACAAG  598
  K  P  A  A  E  E  V  K  P  I  P  A  G  E  L  Q  I  V  D  K
                  140
ATTGACGTCGCCTTCAGAACTGCCGCCACCGCCGCCAACGCCGCCCCCACCAACGACAAG  658
  I  D  V  A  F  R  T  A  A  T  A  A  N  A  A  P  T  N  D  K
                  160
TTCACCGTATTCGAGACCACCTTTAACAAGGCCATCAAGGAGAGCACGGGCGGCACCTAC  718
  F  T  V  F  E  T  T  F  N  K  A  I  K  E  S  T  G  G  T  Y
                  180
GAGAGCTACAAGTTCATTCCCACCCTTGAGGCCGCCGTTAAGCAGGCCTACGCCGCCACC  778
  E  S  Y  K  F  I  P  T  L  E  A  A  V  K  Q  A  Y  A  A  T
                  200
GTCGCATCCGCGCCGGAGGTCAAGTACGCCGTCTTTGAGACCGCGCTGAAAAAGGCGGTC  838
  V  A  S  A  P  E  V  K  Y  A  V  F  E  T  A  L  K  K  A  V
                  220
ACCGCCATGTCCGAGGCCCAGAAGGAAGCCAAGCCCGCCACCGCCACCCCGACCCCCACC  898
  T  A  M  S  E  A  Q  K  E  A  K  P  A  T  A  T  P  T  P  T
                  240
```

Fig. 16 cont.

```
GCAACTGCCGCGGCCGCGGTGGCCACCAACGCCGCCCCCGTCGCTGCTGGTGGCTACAAA   958
  A  T  A  A  A  A  V  A  T  N  A  A  P  V  A  A  G  G  Y  K
     260                 270
ATCTGATCAACTCGCTAGCAATATACACATCCATCATGCACATATAGAGCTGTGTATGTA  1018
  I  *
TGTGCATGCCGTGGCGCCGCGCAAGTTTGCTCATAATTAATTCTTGGTTTTCGTTG     1078
CTTGCATCCACGGAGCGACCGAGCCCGTGGATAGTCGCATGTGTATGTAATTTTTTCTGAG  1138
AAATGTGTATATGTAATTGAGTACTAAAAAAAAAAA                         1181
```

Fig. 16 cont.

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY (IPEA/EPO)

International Application No.: PCT/US94/09024

International Filing Date: 05/08/94 (05 August 1994)

Applicant: ImmuLogic Pharmaceutical Corporation

Receiving Office: RO/EPO

Attorney Docket No.: 075.1 PCT (IMI-040 CP2PC)

Authorized Officer: M. Cupido

VIA FACSIMILE TO 011-49-8923994465
Confirmation Copy Will Follow Via DHL Delivery Within 14 Days

European Patent Office
P.B. 5818 Patentaan 2
NL-2280 HV Rjswijk
NETHERLANDS

RESPONSE TO FIRST WRITTEN OPINION

Dear Sir:

This is in response to a First Written Opinion mailed from the International Preliminary Examining Authority on May 19, 1995 in the above-identified international patent application.

REMARKS

Claims 1 and 2 have been amended to limit the claims to peptides having at least seven, and no more than 100, amino acid residues. Support for this amendment can be found in the specification, for example, at page 8, lines 19-24. In addition, Applicant has submitted herewith substitute page 82, containing newly amended claims 1 and 2.

Novelty

In Section II, Paragraph (1), of the Written Opinion, the Examiner asserts that the subject matter of claims 1-21, 23-28 and 37-43 lacks novelty over WO-A-93/04174 (The University of Melbourne) (D1), except insofar as these claims include the sequences for LPIX-1, LPIX-1.1 and LPIX-2. In particular, the Examiner states that D1 discloses the complete nucleotide sequence of *Lol p* V, as well as the corresponding amino acid sequence of the allergen (Figure 3). The Examiner also notes that D1 teaches the nucleotide sequence of two large fragments of *Lol p* V which are recombinantly expressed as GST fusion proteins (see Figure 4). Based on this disclosure, the Examiner concludes that "peptides **comprising** the amino acid sequences shown in Figure 21 of the present application are known in the prior art."

The Examiner further states that D1 teaches (1) monoclonal antibodies specific for the *Lol p* V fragments disclosed in Figure 4 and (2) diagnostic methods using these *Lol p* V peptides. Based on this disclosure, the Examiner concludes that the subject matter of claims 1-21, 23-28, and 37-43 lacks novelty within the meaning of Article 33(2) PCT.

Claims 1 and 2 have been amended to recite "[a]n isolated peptide of *Lol p* V wherein said peptide comprises at least one T cell epitope of *Lol p* V, said peptide ***having at least 7, but no more than 100 amino acid residues*** comprising an amino acid sequence selected from . . .". As amended, these claims, as well as the claims which depend from them (i.e., claims 3-9, 12-21, 23-28 and 37), are limited to peptides of a specified length and comprising specified sequences, none of which have been previously disclosed. In addition, claims 42 and 43, as filed, are also limited to *Lol p* V peptides of a specified length. None of the specified sequences recited in these claims are taught by D1 and, therefore, it is respectfully submitted that claims 1-9, 12-21, 23-28 and 37 are novel in view of D1.

It is also respectfully submitted that the remaining claims subject to this rejection, i.e., claims 10, 11, and 38-41 are novel in view of D1. Claims 10 and 11 are directed to an isolated peptide of *Lol p* V having a T cell stimulation index of at least about 3.5, and at least about 5.0, respectively. Claims 38-41 are directed to an isolated peptide of *Lol p* V comprising at least one T cell epitope of *Lol p* V and having a positivity index of at least 60 and a mean T cell stimulation index of at least about 2.5, determined in a population of individuals sensitive to *Lol p* V. D1 does not teach or suggest peptides of *Lol p* V having the T cell stimulating capabilities set forth in claims 10, 11 and 38-41. Therefore, these claims are novel in view of D1.

Applicant gratefully acknowledges the Examiner's finding of novelty in Paragraph (2) of Section II with regard to peptides LPIX-1, LPIX-1.1 and LPIX-2.

Inventive Step

I. Peptides LPIX-1, LPIX-1.1 and LPIX-2

In Section III, Paragraph (1) of the Written Opinion, the Examiner asserts that peptides LPIX-1, LPIX-1.1, and LPIX-2, lack inventiveness over of Klysner et al. (1992) *Clin. Exp. Allergy* 22:491-497 (D2). In particular, the Examiner notes that D2 teaches the common presence of hydroxyproline in the N-terminal sequences of Group V allergens from grass pollens. Based on this teaching, the Examiner concludes that it would have been obvious to one ordinarily skilled in the art at the time of Applicant's invention "that variants of *Lol p* V can be isolated where the 5 proline residues at the N-terminus are found to be hydroxyprolines."

It is respectfully submitted that peptides LPIX-1, LPIX-1.1, and LPIX-2 are not obvious in view of D2. D2 compares the N-terminal sequences of Group V allergens purified from grass extracts, including *L. perenne*, *P. pratensis*, and *D. glomerata*. D2 teaches that the N-terminal sequences from these allergens are homologous, and that these sequences contain hydroxyproline and a high content of alanine (see page 495,

column 2, first paragraph). However, D2 does ***not*** teach that the N-terminal sequences from these allergens contain T cell epitopes, much less specific peptides from these sequences which comprise at least one T cell epitope. Therefore, based on the teachings of D2, selected peptides from the N-terminus of *Lol p* V which comprise at least one T cell epitope would not have been obvious to one of ordinary skill in the art at the time of Applicant's invention, let alone the particular peptides having a specified length which are claimed by Applicant, such as LPIX-1, LPIX-1.1, and LPIX-2.

Furthermore, even if D2 did teach that the N-terminus of *Lol p* V contains T cell epitopes, which D2 does not, one ordinarily skilled in the art at the time of Applicant's invention could not have reasonably expected to succeed in selecting and preparing peptides of a specific length comprising such epitopes, based on the teachings of this reference. D2 fails to provide any guidance regarding how to identify or to isolate peptides from *Lol p* V which comprise at least one T cell epitope and which, ultimately, can be used to down regulate an immune response to rye grass in allergic patients. Without any teaching as to which regions of the N-terminus of *Lol p* V contain T cell epitopes, or how to identify these regions, one of ordinary skill in the art at the time of Applicant's invention could not have reasonably expected to succeed in identifying and isolating peptides comprising at least one T cell epitope from *Lol p* V, such as LP1X-1, LP1X-1.1, and LP1X-2, as claimed by Applicant.

In sum, D2 fails to provide any teaching or suggestion which would have made peptides from the N-terminus of *Lol p* V comprising at least one T cell epitope and having a specified length obvious to one ordinarily skilled in the art at the time of Applicant's invention, much less the specific peptides claimed by Applicant (e.g., LPIX-1, LPIX-1.1, and LPIX-2). D2 also fails to provide any guidance which would have provided a reasonable expectation of succeeding in selecting and preparing such *Lol p* V peptides. Therefore, it is respectfully submitted that peptides LPIX-1, LPIX-1.1, and LPIX-2 are inventive in view of D2.

II. Claims 22 and 29-36

In Section III, Paragraph (2) of the Written Opinion, the Examiner asserts that the subject matter of claims 22 and 29-36 is not inventive in view of D1 (WO-A-93/04174). In particular, the Examiner states that these claims are directed to compositions comprising a combination of peptides including at least one peptide from *Lol p* V. The Examiner then states that "the subject matter of these claims is regarded as an obvious and consequently non-inventive combination of features, as the invention consists merely in the association of peptides each functioning in its normal way and not producing any non-obvious working interrelationship."

It is respectfully submitted that claims 22 and 29-36 are inventive in view of D1. Claim 22 is directed to a therapeutic composition comprising a combination of non-obvious peptides from *Lol p* V, each peptide having a specific length and comprising at least one T cell epitope. Claims 29-36 are directed to therapeutic compositions comprising a combination of non-obvious peptides from both *Lol p* V and *Lol p* I, each peptide having a specific length and comprising at least one T cell epitope. The claimed compositions are inventive ***because the peptides themselves are inventive***. At the time of Applicant's invention, therapeutic compositions containing these peptides were not known or obvious, nor were therapeutic compositions containing combinations of these peptides known or obvious.

D1 teaches the nucleotide sequence and predicted amino acid sequence of *Lol p* V. D1 also teaches two large nucleic acid fragments of *Lol p* V, 2P (bases 1-559) and 1H (562-12430), as shown in Figure 4. D1 fails to teach or suggest the isolation of *Lol p* V peptides comprising at least one T cell epitope and having at least 7, but no more than 100, amino acid residues comprising the specific sequences set forth in claim 1.

Applicant was the first to identify and isolate selected peptides of between 7 and 100 amino acids in length, comprising the dominant T cell epitopes of *Lol p* V. At the

time of Applicant's invention, these peptides would ***not*** have been obvious to one of ordinary skill in the art, based on the sequences of the full length *Lol p* V allergen, or the two large fragments taught by D1, which essentially encompass the first and second halves of the full length cDNA encoding *Lol p* V. Of significance is the fact that D1 provides no guidance regarding how to identify and isolate particular dominant epitopes of *Lol p* V, as claimed by Applicant. Therefore, it would have required undue experimentation, with no reasonable expectation of success, for one of ordinary skill in the art to have selected and prepared peptides from *Lol p* V comprising at least one T cell epitope and comprising the specified amino acid sequences claimed by Applicant.

In sum, for the foregoing reasons, it is respectfully submitted that the peptides of claims 22 and 29-36 are inventive in view of D1. Accordingly, the claimed compositions which are made up of these peptides are also inventive.

Enablement

In Section VIII, Paragraphs (1) and (2), of the Written Opinion, the Examiner asserts that claims 5, 14 and 15 are not fully supported by the description, as required under Article 6 PCT. In particular, the Examiner states that Applicant's disclosure fails to support the claimed *in vivo* utility of the peptides recited in these claims, namely their ability to down regulate an immune response specific for *Lol p* V.

It is respectfully submitted that Applicant's disclosure fully supports claims 5, 14 and 15 under Article 6 PCT. These claims are directed to an isolated peptide of *Lol p* V which, when administered to an individual sensitive to *Lol p* V allergen, induces T cells to become nonresponsive or which modifies the lymphokine secretion profile of T cells in the individual. In preferred embodiments of the invention, these peptides are modified to improve solubility and/or exhibit reduced IgE binding, making them safer for use in humans.

Applicant's disclosure describes how to select and prepare the peptides of claims 5, 14 and 15 (see e.g., page 12, beginning at line 7, to page 16). The disclosure also teaches how to administer these peptides in a therapeutic regimen to a *Lol p* V-sensitive individual to modify the allergic response (e.g., B or T cell response) of the individual to *Lol p* V, or to an allergen cross-reactive with *Lol p* V. For example, the disclosure teaches appropriate diluents and carriers which are administered in combination with the claimed *Lol p* V peptides (see e.g., page 21 beginning at line 26, to page 24, line 6), along with appropriate formulations, dosages and routes of administration for the peptides of claims 5, 14 and 15 (see e.g., page 20, beginning at line 25, to page 24, line 6).
In addition, the disclosure provides several working examples which describe in detail the selection and preparation of several of the claimed peptides. For example, Example 2 describes studies used to identify *Lol p* V peptides capable of causing human T cells to proliferate *in vitro* and, ultimately, which are capable of down regulating an immune response specific for *Lol p* V as described in the specification. Example 3 describes an ELISA assay used to assess the IgE reactivity of allergic individuals to *Lol p* V peptides of the invention. This assay can be used to identify preferred peptides which exhibit reduced IgE binding capacity.

Based on the above-summarized guidance provided in Applicant's specification regarding how to select, prepare, and administer to patients the peptides of claims 5, 14 and 15, one of ordinary skill in the art can practice the invention as claimed without undue experimentation. Furthermore, the Examiner has provided no basis, whatsoever, for doubting the asserted *in vivo* utility of the claimed peptides (i.e., the ability to induce T cell non-responsiveness or to modify the lymphokine secretion profile of human T cells).

It is respectfully submitted that the *in vitro* data presented in the specification, obtained from assays performed on T cells from human patients allergic to ryegrass pollen, fully supports the *in vivo* utility of the claimed peptides, as recited in claims 5, 14

and 15. Applicant is not required to present clinical data to support the asserted *in vivo* utility of the claimed peptides in the absence of evidence which would raise doubt as to this utility. No such evidence has been provided. Accordingly, it is respectfully submitted that claims 5, 14 and 15 comply with Article 6 PCT and the Examiner is requested to withdraw this rejection.

Conclusion

For the foregoing reasons, Applicant's responses are believed to obviate the Examiner's objections.

Respectfully submitted,

LAHIVE & COCKFIELD



Jane E. Remillard
Registration No. 38,872
Attorney for Applicant

60 State Street
Boston, MA 02109

Dated: August 18, 1995

Claims

What is claimed is:

1. An isolated peptide of *Lol p* V wherein said peptide comprises at least one T cell epitope of *Lol p* V, said peptide having at least 7, but no more than 100, amino acid residues comprising an amino acid sequence selected from the group consisting of amino acid sequences as shown in Fig. 2 of peptides LPIX-1 (SEQ ID NO:3), LPIX-1.1 (SEQ ID NO:3), LPIX-2 (SEQ ID NO:4), LPIX-2.1 (SEQ ID NO: 4), LPIX-3 (SEQ ID NO:5), LPIX-4 (SEQ ID NO:6) LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-7 (SEQ ID NO:9), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-10 (SEQ ID NO:12), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-13 (SEQ ID NO:15), LPIX-14 (SEQ ID NO:16), LPIX-15 (SEQ ID NO:17), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-18 (SEQ ID NO:20), LPIX-19 (SEQ ID NO:21), LPIX-20 (SEQ ID NO:22), LPIX-21 (SEQ ID NO:23), LPIX-22 (SEQ ID NO:24), LPIX-23 (SEQ ID NO:25), LPIX-24 (SEQ ID NO:26), LPIX-26 (SEQ ID NO:28), and LPIX-27 (SEQ ID NO:29).

2. An isolated peptide of claim 1, said peptide having at least 7, but no more than 10, amino acid residues comprising an amino acid sequence selected from the group consisting of the amino acid sequences as shown in Fig. 2 of peptides LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-8 (SEQ ID NO:10), LPIX-9 (SEQ ID NO:11), LPIX-11 (SEQ ID NO:13), LPIX-12 (SEQ ID NO:14), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), LPIX-20 (SEQ ID NO:22), LPIX-23 (SEQ ID NO:25), and LPIX-26 (SEQ ID NO:28).

3. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index of at least 2.0.

4. A peptide comprising a portion of an isolated peptide of claim 1 which has a T cell stimulation index approximately equivalent to or greater than the T cell stimulation index of said isolated peptide from which it is derived.

5. An isolated peptide of claim 1 which, when administered to an individual sensitive to *Lol p* V allergen, induces T cells to become nonresponsive or modifies the lymphokine secretion profile of T cells in the individual.

US 0873790403P1

Creation date: 10-09-2003
Indexing Officer: TBUI1 - THU-TRANG BUI
Team: OIPEBackFileIndexing
Dossier: 08737904

Legal Date: 02-06-1997

No.	Doccode	Number of pages
1	IMIS	1

Total number of pages: 1

Remarks:

Order of re-scan issued on .....